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ABSTRACT 
This thesis project aimed to collect all mutations in TPM2 and TPM3 genes hitherto found to 
cause congenital myopathies, to perform genotype-phenotype correlations, and to increase our 
understanding of the pathogenetic mechanisms of congenital myopathies caused by mutations 
in the tropomyosin and nebulin genes. Nemaline myopathy (NM), a rare, genetic muscle 
disorder defined on the basis of muscle dysfunction and the presence of structural 
abnormalities in the muscle fibres (i.e. nemaline bodies), is caused by mutations in ten genes 
known to date: Nebulin (NEB), α-actin (ACTA1), α-tropomyosin (TPM3), β-tropomyosin 
(TPM2), troponin T (TNNT1), cofilin 2 (CFL2), KBTBD13, KLHL40, KLHL41 and leiomodin 
3 (LMOD 3). This study concentrated on the investigation of β-tropomyosin and nebulin since 
both have been identified by our group as genes causative of NM. In addition, this study 
focused on α-tropomyosin because it forms dimers with β-tropomyosin. 
        Tropomyosin controls muscle contraction by inhibiting the actin–myosin interaction in a 
calcium-sensitive manner. Mutations in tropomyosin genes may cause NM, cap myopathy, 
congenital fibre-type disproportion (CFTD), distal arthrogryposes (DA) and Escobar 
syndrome. We correlated the clinical picture of these diseases to novel and previously 
published mutations to the TPM2 and TPM3 genes, including 30 mutations causing amino 
acid changes in TPM2 and 20 mutations in TPM3. Most mutations were heterozygous 
changes associated with autosomal dominant disease including 19 novel and 31 previously 
reported mutations. Previous studies found that five mutations in TPM2 and one in TPM3 
caused an increased Ca
2+
 sensitivity, resulting in a hypercontractile molecular phenotype. 
Patients with hypercontractile molecular phenotypes more often had contractures of the limb 
joints (18/19) and jaw (6/19) than those with non-hypercontractile molecular phenotypes 
(2/22 and 1/22).  
        Our in silico predictions show that most tropomyosin mutations affect the tropomyosin–
actin association or tropomyosin head-to-tail binding. We studied the pathogenetic 
mechanisms to which five disease-causing mutations in β-tropomyosin (p.Glu41Lys, 
p.Lys49del, p.Glu117Lys, p.Glu139del and p.Gln147Pro) lead. We showed that four of the 
mutations cause changes in the affinity for actin (p.Lys49del, p.Glu117Lys, p.Glu139del and 
p.Gln147Pro) leading to muscle weakness in patients, while two mutations show defective 
Ca
2+
 activation of contractility (p.Glu41Lys and p.Glu117Lys). We also mapped the amino 
acids altered by the mutations to regions important for actin binding and note that two of the 
mutations cause altered protein conformations accounting for an impaired actin affinity.   
        Nebulin (NEB) is a giant 600–900-kDa filamentous protein that is a part of the skeletal 
muscle’s thin filament. Because of its large size and the difficulty of extracting nebulin in its 
native state from muscle, its functions remain partly unknown. To study nebulin in more 
detail, we produced four wild-type (wt) nebulin super-repeats (283–347-amino acids long) 
and five corresponding patient mutantion constructs. We included three missense mutations 
(p.Glu2431Lys, p.Ser4665Ile and p.Thr5681Pro) and two in-frame deletions 
(p.Arg2478_Asp2512del and p.Val3681_Asn3686del) in the study. The mutations were 
identified in patients with NM or distal myopathy. We performed F-actin and tropomyosin-
binding experiments for the nebulin fragments using co-sedimentation and GST pull-down 
assays. We also tested wt nebulin fragment (super repeats 9, 14, 18 and 22) affinity to β–
 
 
tropomyosin wt and six mutants (Lys7del, Glu41Lys, Lys49del, Glu117Lys, Glu139del and 
Gln147Pro) using the GST-pull-down assay. Our results demonstrate actin–nebulin 
interactions and, for the first time, tropomyosin–nebulin interactions in vitro, and show that 
the interactions are altered by disease-causing mutations. 
        These results indicate that mutations affecting both tropomyosin and nebulin lead to 
changes in protein interactions, suggesting that an abnormal interaction between aberrant thin 
filament proteins is a pathogenetic mechanism in NM and related disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TIIVISTELMÄ 
Väitöskirjatyön tavoitteena oli kerätä kaikki tähän mennessä tunnetut mutaatiot TPM2 ja 
TPM3 geeneistä, jotka aiheuttavat synnynnäisiä myopatioita. Halusimme tehdä näistä 
genotyyppi-fenotyyppi-korrelaatioita sekä toiminnallista analyysiä proteiineilla 
selvittääksemme taudin patogeneesia. 
        Nemaliinimyopatia (NM) on harvinainen geneettinen lihassairaus jonka oireita ovat 
lihaksen toiminnan häiriöt ja lihassyiden rakenteelliset poikkeavuudet, niin sanotut 
nemaliinikappaleet. NM:aa aiheuttavat mutaatiot kymmenessä geenissä: nebuliini (NEB), 
aktiini (ACTA1), α-tropomyosiini (TPM3), β-tropomyosiini (TPM2), troponiini T (TNNT1), 
kofiliini 2 (CFL2), KBTBD13, KLHL40, KLHL41 ja leiomodiini 3 (LMOD 3). 
Tutkimuksemme keskittyi β-tropomyosiiniin ja nebuliiniin, sillä ne on todettu NM:n 
aiheuttajageeneiksi ryhmämme aiemmissa tutkimuksissa. Myös α-tropomyosiinia tutkittiin, 
sillä se muodostaa dimeereitä β-tropomyosiinin kanssa. Tropomyosiini osallistuu 
lihassupistukseen säätelemällä aktiinin ja myosiinin sitoutumista toisiinsa. Solunsisäinen 
kalsiumin (Ca
2+
) määrä säätelee lihassupistusta. Mutaatiot tropomyosiinigeeneissä voivat 
aiheuttaa NM:aa, cap-myopatiaa, syy-tyyppi-epäsuhtaa (congenital fibre-type disproportion; 
CFTD), distaalista artrogrypoosia (DA) ja Escobarin oireyhtymää.        
        Olemme verranneet sairauksien kliinistä kirjoa sekä uusia ja tunnettuja mutaatioita 
TPM2 ja TPM3 geeneissä. Mukana on 30 mutaatiota TPM2- ja 20 mutaatiota TPM3- 
geeneistä. Useimmat mutaatiot ovat heterotsygoottisia muutoksia, jotka aiheuttavat 
autosomaalisen dominantin taudin. Tutkimuksessa oli mukana 19 uutta ja 31 tunnettua 
mutaatiota TPM2 ja TPM3 geeneissä. Aiemmissa tutkimuksissa on näytetty että TPM2 ja 
TPM3 mutaatiot aiheuttavat kohonnutta Ca
2+
 herkkyyttä aiheuttaen hyperkontraktiilin 
molekulaarisen fenotyypin. Potilailla, joilla oli hyperkontraktiili molekulaarinen fenotyyppi 
oli useammin kontraktuuroja raajojen nivelissä (18/19) ja leuassa (6/19) kuin potilailla joilla 
ei ollut hyperkontraktiilia fenotyyppia (2/22 ja 1/22).   
        In silico mallintaminen paljasti että useimmat tropomyosiini-mutaatiot vaikuttavat 
tropomyosiinin ja aktiinin sitoutumiseen toisiinsa tai tropomyosiinin päästä häntään (head-to-
tail) sitoutumiseen. Tutkimme viiden  β-tropomyosiini-mutaation (p.Glu41Lys, p.Lys49del, 
p.Glu117Lys, p.Glu139del ja p.Gln147Pro) aiheuttamaa patogeneesia. Näytimme, että neljä 
mutaatiota muuttaa tropomyosiinin sitoutumista aktiiniin (p.Lys49del, p.Glu117Lys, 
p.Glu139del ja p.Gln147Pro), joka on aiheuttanut näiden potilaiden lihasheikkouden.  
Mutaatiot p.Glu41Lys, p.Glu117Lys aiheuttavat häiriön Ca
2+
 aktivoimassa lihassupistuksessa. 
Olemme paikantaneet mutaatiot β-tropomyosiinissa alueille, jotka ovat tärkeitä aktiiniin 
sitoutumisessa. Kaksi mutaatiota (p.Lys49del ja p.Glu139del) muuttaa proteiinin 
konformaatiota aiheuttaen β-tropomyosiinin alentunutta affiniteettia aktiiniin.            
        Nebuliini on noin 600-900 kDa jättiläisproteiini, joka on osa lihaksen ohutta filamenttia. 
Koska nebuliini on kooltaan suuri ja vaikeasti eristettävä, sitä on tutkittu vähän. Olemme 
tuottaneet villityypin (vt) nebuliinin toistoajaksoja (283-347 amino happoa) ja viisi vastaavaa 
mutanttia. Kolme missense mutaatiota (p.Glu2431Lys, p.Ser4665Ile ja p.Thr5681Pro) ja kaksi 
in-frame deleetiota (p.Arg2478_Asp2512del ja p.Val3681_Asn3686del) olivat mukana 
tutkimuksessa. Mutaatiot aiheuttavat NM:aa tai distaalistamyopatiaa. Olemme tehneet aktiinin 
 
 
ja tropomyosiinin sitoutumiskokeita nebuliinifragmenteille käyttäen ko-sedimentaatio- ja 
GST-pull-down-menetelmiä. 
        Testasimme myös vt nebuliinifragmenttien (toistoajaksot 9, 14, 18 and 22) sitoutumista 
vt β–tropomyosiiniin ja kuuteen mutanttiin (Lys7del, Glu41Lys, Lys49del, Glu117Lys, 
Glu139del and Gln147Pro) käyttäen GST-pull-down menetelmää. Teimme F-aktiini-
nebuliini-interaktiokokeita ja ensimmäistä kertaa tropomyosiini-nebuliini sitoutumisen in 
vitro. Osoitimme että, vt ja tautimutaation sisältävien fragmenttien sitoutuminen eroavat 
toisistaan.  
       Tulokset osoittavat, että mutaatiot sekä tropomyosiinissa että nebuliinissa muuttavat 
proteiinien sitoutumista toisiinsa. Sitoutumiserot muuntuneiden ohuen filamentin proteiinien 
välillä ovat patogeneettisia mekanismeja NM:ssa ja sen kaltaisissa myopatioissa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Congenital myopathies are rare. Taken together, the estimated incidence for all congenital 
myopathies reaches approximately 0.06 per 1000 live births. Congenital myopathies are 
characterised by generalised muscle hypotonia and weakness of varying severity usually 
beginning at birth. Myopathies cannot be definitely distinguished from each other nor from 
other congenital muscle disorders on clinical grounds alone; diagnosis depends on 
characteristic muscle biopsy findings (Jungbluth and Wallgren-Pettersson 2013). Nemaline 
myopathy (NM), first described in 1963 in two independent reports (Shy et al. 1963, Conen, 
Murphy & Donohue 1963), is a rare genetic muscle disorder, but represents one of the most 
common congenital myopathies. The autosomal dominant forms (MIM 161800) and the more 
common autosomal recessive forms (MIM 256030) are usually histologically similar 
(Jungbluth and Wallgren-Pettersson 2013). Both display clinical and genetic heterogeneity. 
To date ten different causative genes have been identified for NM: nebulin (NEB), slow 
skeletal muscle -actin (ACTA1), -tropomyosin (TPM2), slow -tropomyosin (TPM3), 
troponin T (TNNT1), cofilin 2 (CFL2), a member of the BTB/kelch protein family 
(KBTBD13) and kelch-like family members 40 and 41 (KLHL40 and KLHL41) and 
leiomodin-3 (LMOD3) (Laing et al. 1995, Pelin et al. 1999, Nowak et al. 1999, Johnston et al. 
2000, Donner et al. 2002, Agrawal et al. 2007, Sambuughin et al. 2010, Ravenscroft et al. 
2013b, Gupta et al. 2013, Yuen et al. 2014). Wide variability in the clinical spectrum of NM 
exists ranging from severe to mild. The European Neuromuscular Centre International 
Consortium on NM determined six clinical categories for NM according to the severity of the 
disease and the presence or absence of unusual or associated features (Wallgren-Pettersson 
and Laing 2000, Wallgren-Pettersson et al. 2011). In addition, a wide overlap in the clinical 
and histological continuum of these diseases exists.  We studied the mutational spectrum in 
the TPM2 and TPM3 genes in NM, cap myopathy, core-rod myopathy, congenital fibre-type 
disproportion, distal arthrogryposes and Escobar syndrome, and looked for genotype–
phenotype correlations. NM was thought to be a disorder of thin filament proteins, but recent 
discoveries of mutations in non-thin filament genes challenged this model (Gupta et al. 2013). 
In order to understand the pathogenetic mechanisms underlying NM, it is necessary to 
understand the normal interactions of these proteins. Mutations in the genes which encode 
parts of the thin filament may disrupt the order and assembly of sarcomeric proteins. Our goal 
was to understand the pathogenetic mechanisms of the congenital myopathies caused by 
mutations in the tropomyosin and nebulin genes by investigating how these mutations affect 
protein function and protein interactions.
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REVIEW OF THE LITERATURE 
 
1 SKELETAL MUSCLE 
Muscle tissue generates a mechanical force enabling for example locomotion, breathing, 
cardiac activity and digestion. Three main classes of muscle exist: skeletal muscle, heart 
muscle and smooth muscle. Skeletal muscle and heart muscle are striated muscles, while 
smooth muscle is non-striated. Heart muscle and smooth muscle contract involuntarily and 
only striated muscles are under voluntary control (Dubowitz and Sewry 2007). Skeletal 
muscle makes up approximately 40% of the body mass in humans. Muscles are bound to 
bones by tendons forming bundles of muscle fibres surrounded by layers of connective tissue.  
The diameter of an individual muscle fibre varies depending on t person and the specific 
muscle. The diameter of an adult male quadricep muscle fibre diameter varies between 40 and 
80 µm. Muscle fibres form through the fusion of single cells and are, thus, multinucleated and 
enveloped by sarcolemma with the nuclei situated under the sarcolemma. The basal lamina is 
the external layer of the muscle fibre secreted by muscles which is composed of many 
myofibrils separated by the intermyofibrillar spaces (Dubowitz and Sewry 2007, Alberts et al. 
1994).  
 
1.1 Muscle fibre types 
Most skeletal muscles contain a mixture of fibres which differ in their physiological and 
biochemical properties. Muscle pathology is concentrated on the identification of fibre types 
and the ways in which they are affected by pathological processes (Dubowitz and Sewry 
2007). Two major fibre types can be identified by enzyme histochemistry: type 1 fibres have a 
high oxidative and low glycolytic activity, while type 2 fibres have a low oxidative and high 
glycolytic activity (Dubowitz and Pearse 1960). The most common nomenclature for fibre 
types is based on the appearance of the tissue after staining with adenosine triphosphatase 
(ATPase), both with and without preincubation at an acid pH (Brooke and Kaiser 1970). 
Three main fibre types are seen in normal muscle, including types type 1, 2A and 2B, as well 
as an additional immature subtype 2C (Dubowitz and Sewry 2007). For use in routine 
diagnostics, a newly developed immunohistochemical myosin double-staining method exists 
for the identification of fibre types, including highly atrophic fibres. With the double-staining 
method, distinguishing between type I (ATPase type 1), IIA (ATPase type 2A), IIX (ATPase 
type 2B) and remodeled ATPase type 2C fibres becomes possible, expressing both fast and 
slow myosins using a one-slide technique. Immunohistochemical double-staining of myosin 
heavy chain isoforms can be used as an alternative to the conventional ATPase staining 
method in routine histopathology (Raheem et al. 2010). 
        The motor unit includes a nerve with a cell body and an axon innervating the muscle 
fibres. The muscle fibres from one motor unit are uniform in type and randomly scattered. 
Motor units are classified according to their speed of contraction and resistance to fatigue, and 
include three main types: fast twitch, fatigue sensitive (FF); fast twitch, fatigue resistant (FR); 
and slow twitch, fatigue resistant (S) (Schiaffino, Hanzlikova & Pierobon 1970). Fatigue 
resistance is related to oxidative capacity and mitochondrial content. Fibres are classified as 
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follows: slow twitch, oxidative (SO), which corresponds to histochemical type 1 fibres; fast 
twitch, glycolytic (FG), which correspond to 2B; and fast twitch, oxidative glycolytic (FOG), 
which, correspond to 2A (Burke et al. 1973). Classification studies have relied on animal 
studies, with evidence suggesting similarities in humans. In contrast to other species, all 
human striated muscles contain mixed fibre types and show light and dark fibres in the 
ATPase stain. Different muscles have a characteristic proportion of fibre types (Dubowitz and 
Sewry 2007).  
 
1.2 The Muscle sarcomere 
Muscle fibres are composed mainly of myofibrils. Each myofibril contains a bundle of 
myofilaments regularly aligned to form repetitive structures known as sarcomeres. The 
ordered arrangement of different proteins in the sarcomere gives rise to the striated pattern of 
skeletal muscle. The sarcomere is composed of a dark anisotropic band (the A-band) flanked 
by light isotropic bands (I-bands). A narrow dense line (the M-band), which is flanked by the 
slightly paler H-zone, lies in the central region of the A-band. A narrow dense Z-disc marks 
the longitudinal borders of each sarcomere. The length of each sarcomere is around 2.0–3.0 
µm at rest. During muscle contraction, the I-band filaments slide towards the centre of the A-
band and the sarcomere becomes shorter (Dubowitz and Sewry 2007).  
        The A-band consists of thick myosin filaments which are 15–18 nm in diameter and 
approximately 1.5 µm long. The myosin molecules are double-stranded helixes with rod-
shaped tails and two heavy meromyosin heads joined by a flexible shaft of light meromyosin. 
The region where the light meromyosin tails overlap without myosin heads is known as the 
pale H-zone and is situated at the centre of the A-band. The M-lines are three to five lines 
across the thick filaments and are thought to play a role in connecting myosin filaments and 
stabilising the A-band. Myomesin, skelemin, M protein and a fraction of creatine kinase are 
located in the M-line. The I-band filaments are composed mainly of a double helix of 
filamentous actin and are 6–7 nm in diameter. The Z-disc anchors actin filaments at the one 
end and the other end interdigitates with myosin (Figure 1). Each myosin filament is 
surrounded by six actin filaments. In addition to their structural roles, and their roles in the 
motor function of the sarcomere, sarcomeric proteins are also involved in signalling pathways 
(Dubowitz and Sewry 2007). Tropomyosin resides in the actin helix grooves and has regular 
attachment sites to actin. Troponin complexes are attached to the tropomyosin dimer.    
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Figure 1. Structure of striated muscle sarcomere. Schematic presentation showing the main 
components of the sarcomere. The A-band comprises myosin filaments crosslinked at the centre by the 
M-band assembly. Thin actin-containing filaments are tethered at their barbed end to the Z-disc and 
interdigitate with the thick filaments in the A-band. Two giant proteins contribute to the structure of 
the Z-disc. Nebulin (800 kDa) runs along the thin filaments and overlaps in the Z-disc (Pappas et al. 
2008). The 3-MDa, 1-μm-long protein titin runs between the M-line and the Z-disc (Young et al. 
1998). Tropomyosin binds nebulin in the thin filament (Marttila et al. 2014b). 
 
1.2.1 The Z-disc 
The Z-disc determines the borders to adjacent sarcomeres, allows force transmission in 
myofibrils during muscle contraction and plays a role in signalling and stretch sensing. The 
major components of Z-discs include α-actinin and actin. The actins of the adjacent sarcomers 
connect to form layers of the Z-discs (Figure 1). The thickness of the Z-disc depends on the 
fibre-type: in fast muscle fibres, the diameter is 30–50 nm, while in slow and cardiac muscle 
fibres it is 100–140 nm (Luther et al. 2003).    
        Interest in the interacting partners of the Z-disc protein α-actinin, is increasing given that 
Z-disc abnormalities occur in a number of neuromuscular disorders (Dubowitz and Sewry 
2007). Thus, the proteins studied include telethonin (cap protein), myozenin, zeugmentin, 
syncoilin, vinculin, γ-filamin, obscurin, myotilin, nebulin and titin (Stromer 1995, Takada et 
al. 2001, Selcen and Engel 2004, Chitose et al. 2010, Gregorio et al. 1998).  Myopalladin, 
myotilin, nebulin and titin has been suggested to play a role in Z-disc assembly (Bang et al. 
2001, Carlsson et al. 2007, Labeit, Ottenheijm & Granzier 2011, Ottenheijm, Granzier 2010, 
Gregorio et al. 1998). The giant proteins of the sarcomere, nebulin and titin, are also attached 
to the Z-disc. The C-terminus of nebulin is attached to the Z-disc and extends to the I-band. 
The titin molecule reaches from the Z-disc to the M-line. Furthermore, titin molecules overlap 
in the Z-disc and the M-line in adjacent sarcomeres (Dubowitz and Sewry 2007). Studies on 
nebulin knockout mice suggest that myofibrils are laterally linked at the level of the Z-disc by 
desmin filaments that bind to nebulin (Tonino et al. 2010).      
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1.2.2 The thick filament and its proteins 
The thick filament is formed by myosin and myosin-binding proteins. The myosin chains of 
opposing thick filaments are bound together by M-band proteins such as myomesin (Pinotsis 
et al. 2008). In total, 294 myosin molecules form the backbone of 1.59 µm long and 1 nm 
thick filament (Berg, Powell & Cheney 2001). 
 
1.2.2.1 Myosin 
The first muscle proteins purified included myosin and actin. Modifying actomyosin solution 
from a high ionic strength into a solution with a lower ionic strength, produced threads which 
contracted when ATP was added (Szent-Györgyi 1943). Early electron microscopic images 
showed the asymmetric structure of rabbit skeletal muscle myosin: two polypeptide chains 
dimerise forming a C-terminal coiled-coil tail and the N-terminus of each chain forming a 
large globular head (Huxley 1963, Slayter and Lowey 1967). Myosin is a highly conserved 
protein found in all eukaryotic cells. It acts as a molecular motor converting the chemical 
energy of ATP hydrolysis into a mechanical force (Figure 2) for diverse cellular occurences 
such as cytokinesis, phagocytosis and muscle contraction (Ruppel and Spudich 1996b, Ruppel 
and Spudich 1996a). In humans, 40 genes encode myosins (Berg, Powell & Cheney 2001). 
Myosins form a diverse superfamily grouped into two classes: the unconventional and 
conventional class II two-headed myosins that form filaments in striated muscle, smooth 
muscle and non-muscle cells (Sellers 2000). The class II muscle myosin is a hexameric 
protein composed of two myosin heavy-chain (MyHC) subunits and two pairs of non-
identical light-chain subunits. MyHCs associate into dimers through a coiled–coil interaction 
along its long tail (Schiaffino, Reggiani 1994). Several striated muscle MyHC isoforms exist, 
encoded by different genes and expressed in a tissue- and developmental-specific manner 
(Schiaffino and Reggiani 1994). Three major MyHC isoforms are found in adult human 
skeletal limb muscle. MyHC I (slow/ß-cardiac MyHC) is encoded by MYH7 and is expressed 
in slow, type 1 muscle fibres and in the ventricles of the heart. MyHC IIa (MYH2) is 
expressed in fast, type 2A muscle fibres, while MyHC IIX (MYH1) is expressed in fast, type 
2B muscle fibres. The differing contractile and physiological properties of the three different 
muscle fibre types are partly determined by different MyHCs (Tajsharghi and Oldfors 2013). 
Myosin myopathies have variable clinical phenotypes depending on the mutated isoform and 
the type and location of the mutation. They include distal arthrogryposis syndromes 
(mutations in MYH3 and MYH8), autosomal dominant myopathy (mutations in MYH2), 
familial hypertrophic cardiomyopathy, myosin storage myopathy and Laing distal myopathy 
(mutations in MYH7) (Tajsharghi and Oldfors 2013, Oldfors A 2008). 
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Figure 2. Schematic diagram of thin and thick filament organisation and contraction process. The thin 
filament consists of actin, the troponin complex (TnT, TnC and TnI) and α- and β-tropomyosin dimer. 
The thick filament is composed of myosin heavy and light chains. The sarcomere produces muscle 
contraction by sliding of myofilaments: the myosin heads interact with actin and pull it towards the 
center of the sarcomere resulting in shortening of the sarcomere. 
 
1.2.3 The thin filament and its proteins 
The globular protein actin, which is polymerised polymerized into elongated filaments of 
double helical strands is the main component of the thin filament. The fibrous protein 
tropomyosin is located in the groove formed between actin strands and is polymerised head-
to-tail along the actin filament. Troponin, a globular complex consisting of three proteins 
(troponin C, troponin I and troponin T), is associated with each tropomyosin. Nebulin is a 
giant protein reaching across the entire length of the thin filament, while tropomodulin, a 
capping protein, stabilise the thin filament (Ochala 2008). 
 
1.2.3.1 Actin 
At least six different structural genes for actin are expressed in skeletal muscle: α-actin, α-
cardiac, α-smooth muscle, β-actin, γ-actin and γ-enteric actin (Vandekerckhove and Weber 
1978). With the exception of those in inner-ear hair cells where only γ-actin is expressed, β-
actin and γ-actin form the actin cytoskeleton in human non-muscle cells (Zhu et al. 2003). The 
main protein component of the skeletal muscle thin filament is α-actin; thus, a polymerised α-
actin dimer forms the backbone of the thin filament. The interaction between α-actin and 
various myosin isoforms of the thick filament is ATP-driven and generates the force 
necessary for muscle contraction in the sliding filament model of muscle contraction (Huxley 
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and Niedergerke 1954). Actin has three binding sites for nebulin and binds tropomyosin, the 
troponin complex and several other proteins (Lukoyanova et al. 2002).  
        The first disease-causing mutations in the human skeletal muscle α-actin gene (ACTA1) 
were associated with two different muscle diseases: ‘congenital myopathy with excess thin 
myofilaments’ (actin myopathy) and NM (Nowak et al. 1999). Subsequently, approximately 
200 different ACTA1 mutations have been identified, with 90% resulting in dominant disease 
often arising de novo, and 10% resulting in recessive disease (Nowak, Ravenscroft & Laing 
2013). ACTA1 mutations cause 20–25% of all NM, and 50% of severe NM. The gene is small 
and relatively easy to analyse. Most mutations (90%) are dominant missense changes. To 
date, no missense polymorphisms have been reported in ACTA1 (North et al. 2014). Many 
researchers have studied the normal actin function and the functional consequences of ACTA1 
mutations in cell cultures, animal models and patient tissue samples, linking various ACTA1 
mutations to have different functional effects. The pathophysiology of recessive ACTA1 
disease is straightforward in that the disease is caused by genetic or functional null mutations. 
Biochemical studies demonstrated that some mutant actins failed to fold properly and were, 
therefore, non-functional proteins. The use of small molecules to sensitise the contractile 
apparatus to Ca
2+
 shows promise as therapeutic treatment for patients with various 
neuromuscular disorders, including ACTA1 disease (Nowak, Ravenscroft & Laing 2013). 
 
1.2.3.2 Nebulin 
Nebulin is one of the largest genes in the human genome, with 183 exons encoding a 26 000- 
bp mRNA giving rise to a 600–900-kDa protein (Donner et al. 2004). The name nebulin is 
derived from ‘nebulous’ because the function of the gene was obscure for many years 
(Ottenheijm and Granzier 2010, Pappas et al. 2011). 
        Nebulin is a muscle protein expressed in the thin filaments of striated muscle, and 
approximately 3% of myofibrillar mass is nebulin in the sarcomere (Wang and Wright 1988) 
and has a highly repetitive protein structure (Figure 3). Approximately 97% of the 
polypeptide consists of 30–35 amino acid–long modules arranged into simple repeats or super 
repeats (Donner et al. 2004). Seven small repeats are assembled to form a super-repeat, where 
the similarity between the super-repeats is stronger than between the single 35 amino acid–
containing repeats (Pfuhl, Winder & Pastore 1994). The repeat modules contain conserved 
SDXXYK-actin-binding motifs (Jin and Wang 1991a, Jin and Wang 1991b) and proposed 
WLKGIGW-tropomyosin binding sites (Labeit et al. 1991, Labeit and Kolmerer 1995). The 
nebulin repeat regions have a transient α-helical conformation (Pfuhl, Winder & Pastore 
1994). There is no heptad repeat of hydrophobic residues indicating that nebulin repeats are 
not dimerised into a coiled–coil (Labeit et al. 1991). The 8-kDa N-terminal and the 20-kDa C-
terminal ends contain unique protein domains. The C-terminus is anchored to the Z-disc of 
the muscle sarcomere and contains a conserved src homology 3 (SH3) domain (Donner et al. 
2004). The isolation of rabbit skeletal muscle nebulin was successful in a fully denatured 
form, which bound to actin, β-actinin and tropomodulin, indicating the preservation of some 
of its in vivo functions (Chitose et al. 2010). 
        Nebulin size correlates with thin filament lengths in vertebrates, suggesting that nebulin 
functions as a molecular ruler to determine thin filament length (Wang and Wright 1988, 
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Labeit et al. 1991, Kruger, Wright & Wang 1991). This hypothesis was supported by data 
from nebulin knockout mice. Nebulin may guide and facilitate actin polymerisation (internal 
super-repeats), terminate polymerisation (end regions) and maintain the thin filament length 
(Bang et al. 2006, Witt et al. 2006, Pappas, Krieg & Gregorio 2010). Fluorescent microscopy 
suggests that nebulin specifies the minimum thin filament length and acts in concert with 
nebulin-independent mechanisms to generate thin filaments of varying lengths that are 
functionally optimised for the contractile properties of different muscles (Castillo et al. 2009). 
A mini-nebulin was created to reduce the size of nebulin for experimental purposes: 18 super-
repeats were removed (SR 4–21), leaving the unique N- and C -termini and 4 remaining 
super-repeats intact (SR 1–3 and 22). This resulted in a shorter molecule that retained all of its 
known unique binding sites. Mini-nebulin studies combine previous models, suggesting that 
nebulin dictates the minimal length of the filaments by preventing actin depolymerisation and 
through stabilisation mechanisms. Replacement of nebulin with mini-nebulin in skeletal 
myocytes, thin filaments extended beyond the end of mini-nebulin. However, under 
conditions that promote actin filament depolymerization, filaments associated with mini-
nebulin were maintained at lengths either matching or longer than mini-nebulin. This 
indicates that mini-nebulin is able to stabilise portions of the filament it has no contact with 
(Pappas, Krieg & Gregorio 2010). In addition, nebulin appears to possess functions beyond 
thin filament length control, such as contractility, specification of the Z-disc structure and 
maintaining inter-myofibrillar activity. During contraction, nebulin depresses the production 
of force by reducing the thin–thick filament overlap and enhances crossbridge cooperative 
binding in skeletal muscle (Lawlor et al. 2011, Bang et al. 2006, Witt et al. 2006, Bang et al. 
2009). In vitro binding studies, in vivo data from knockdown mice and differential splicing 
studies support the important role of nebulin in the specification of the Z-disc structure. In the 
absence of nebulin, Z-discs are significantly wider than normal (Witt et al. 2006, Tonino et al. 
2010, Buck et al. 2010). Nebulin isoform diversity is high in skeletal muscle and in the brain, 
and may have similar functions in the brain and in skeletal muscle, although patients with 
nebulin mutations usually exhibit normal cognition (Laitila et al. 2012). In a study of four 
patients, low levels of nebulin may explain their poor prognosis resulting from NM due to 
nebulin mutations. This finding may be clinically useful, but should be examined in a larger 
sample of patients (Lawlor et al. 2011). 
        The size of the human nebulin gene is 249 kb containing 183 exons. The translation 
initiation codon is in exon 3, while the stop codon and 3' untranslated region (UTR) are 
located at exon 183. Nebulin has many different isoforms produced by alternative splicing of 
exons 63–66, 82–105, 143–144 and 166–177. Mouse exons 127 and 128 corresponding to 
human exons 143–144 show variable expressions during development (Donner et al. 2006). 
An 8.2-kb triplicate region where 8 exons repeat 3 times (exons 82–89, 90–97 and 98–105) is 
situated in the central region of the gene (Gunning, O'Neill & Hardeman 2008). Mouse 
nebulin contains 165 exons in a 202-kb segment of DNA and in addition to skeletal muscle, 
low levels of nebulin expression have been reported in the mouse heart muscle (Kazmierski et 
al. 2003). In the human heart, nebulin is replaced by a small nebulin-like protein called 
nebulette (Moncman and Wang 1995).  
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Figure 3. Schematic presentation of nebulin structure and the interacting proteins. Modified from 
Marttila et al. 2014 Skeletal Muscle 1;4:15. 
 
No mutational hotspots have been found in nebulin, while normally compound heterozygous 
patients exhibit their own unique mutations. This makes routine mutation analysis of the 
complete gene difficult (Pelin et al. 1999, Lehtokari et al. 2006, Donner et al. 2004, Pelin et 
al. 2002). Mutations primarily include small deletions or point mutations (Pelin et al. 1999, 
Lehtokari et al. 2006, Pelin et al. 2002, Kiiski et al. 2013). The first large founder mutation 
found in nebulin was identified as the 2.5kb deletion of exon 55 common among the 
Ashkenazi Jewish population occurring globally (Anderson et al. 2004, Lehtokari et al. 2009). 
A comparative genomic hybridisation microarray designed for known NM genes identified 
two novel deletions. To date, the largest deletion characterised in nebulin (∼53kb) includes 24 
exons, with a further one 1-kb deletion identified covering 2 exons (Kiiski et al. 2013). 
 
1.2.3.3 Tropomyosins 
Tropomyosins (Tms) are a group of highly conserved actin-binding proteins, that together 
with troponins, regulate muscle contraction. The tropomyosins are α-helical coiled–coil 
proteins. They polymerise head-to-tail and overlap by eight or nine amino acids. Tropomyosin 
dimers are located in the grooves of actin filaments, providing structural stability and 
modulating filament function (Phillips et al. 1979, Matsumura, Yamashiro-Matsumura & Lin 
1983, Holmes et al. 1990, Lin et al. 1997). Tropomyosins have a seven-fold repeated amino 
acid sequence motif, the heptad repeat (abcdefg). The a and d residues are hydrophobic and 
form the helix interface, while b, c, e, f and g are hydrophilic and form the solvent-exposed 
part of the coiled–coil (Perry 2001, Lupas 1996). Tropomyosin binds F-actin roughly in a 1:7 
molar ratio (Eaton, Kominz & Eisenberg 1975). Each tropomyosin molecule is subdivided 
into α- and β-zones, whereby the actin-binding properties of the α-zones were identified over 
30 years ago (McLachlan and Stewart 1976). In the relaxed state, tropomyosin forms contacts 
with actin through positively charged residues in the N-terminal part of the α-zone and 
through acidic residues on the C-terminal side of the α-zone (Brown et al. 2005). Recently, 
the exact structural model of the actin-binding residues in tropomyosin were discovered in the 
closed state (Barua et al. 2013, Holmes and Lehman 2008, Lehman et al. 2013, Li et al. 2011).    
        Tropomyosins are encoded by four different genes TPM1, TPM2, TPM3 and TPM4 
(Pittenger, Kazzaz & Helfman 1994). The tropomyosin genes TPM1, TPM2 and TPM3 are 
expressed in skeletal muscle-encoding isoforms Tm1 (Tmfast), Tm2 (Tm) and Tm3 
(Tmslow). TPM1 is expressed in fast muscle fibres and in cardiac muscle (Gunning et al. 
1990). TPM2 is expressed in both slow and, to a lesser extent, in fast muscle fibres. TPM3 is 
expressed mostly in slow muscle fibres (Perry 2001). More than 40 different tropomyosin 
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isoforms are generated due to the use of different promoters or variable intragenic splicing 
(Pittenger, Kazzaz & Helfman 1994, Dufour et al. 1998, Cooley and Bergtrom 2001). 
Tropomyosins can be divided into a group with a high molecular weight containing 284–281 
amino acid residues and into a group with a low molecular weight group of tropomyosins 
containing 245–251 amino acid residues. All of the tropomyosin isoforms isolated consist of 
multiples of approximately 40 amino acids, each of which is thought to interact with an actin 
monomer subunit when complexed with F-actin (Perry 2001). When both - and -
tropomyosins are expressed, -heterodimers are preferentially formed over -homodimers, 
while -homodimers are rare. The dimer preference can be affected by mutations (Perry 2001, 
Corbett et al. 2005).  
        The first mutation characterised as the cause of NM in the - tropomyosin was 
p.Met9Arg (Laing et al. 1995). Conversely, the first mutations in the -tropomyosin gene 
were identified as rare causes of NM (Donner et al. 2002). Mutations in TPM2 were found to 
cause dominant distal arthrogryposis (Tajsharghi et al. 2007a, Sung et al. 2003a). The correct 
classification of congenital myopathies by molecular testing has proved challenging because 
of the size and heterogeneity of the genes involved. Because of this, the proportion of disease 
caused by different genes is largely unknown. Both TPM2 and TPM3 have been associated 
with 4.3% of disease (Citirak et al. 2014). When diagnosing patients, if nemaline rods are 
restricted to type 1 muscle fibres, TPM3 analysis is recommended. TPM2 analysis should be 
considered for mild dominant disease (North et al. 2014). 
. 
 
1.2.3.4 The troponin complex 
Troponin C, I and T, encoded by TNNT1, TNNT2 and TNNT3, form a complex which, 
together with tropomyosin, regulates the actin–myosin interactions in muscle contraction in a 
calcium-sensitive manner. Troponin C binds Ca
2+
, troponin I binds to actin and inhibits the 
actomyosin ATPase and troponin T links the troponin complex to tropomyosin (Greaser and 
Gergely 1973). Troponin I and T exhibit separate isoforms for cardiac, type 1 and type 2 
muscle fibres. Troponin C has two isoforms: one for cardiac and type 2 fibres and another for 
type 1 muscle fibres (Clarke 2008).  
        Previous studies determined that the mutations in troponins cause familial hypertrophic 
cardiomyopathy (Bonne et al. 1998, Revera et al. 2008), NM among the Amish (Johnston et 
al. 2000, van der Pol et al. 2014) and DA type 2B (Sung et al. 2003b).  
 
 
1.2.3.5 Tropomodulin 
Tropomodulin was first detected in the erythrocyte membrane as a tropomyosin-binding 
protein with a molecular mass of 40 kDa (Fowler 1987). It was localised in the sarcomere 
through immunofluorescence staining to a site at or near the pointed ends of the skeletal 
muscle thin filaments (Fowler et al. 1993). Tropomodulin is also found near the pointed ends 
of the thin filaments in cardiac muscle. In nanomolar concentrations, tropomodulin blocks 
elongation and depolymerisation at the pointed ends of tropomyosin-actin filaments. Pointed-
end capping by tropomodulin helps to maintain constant lengths of tropomyosin-containing 
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actin filaments in skeletal muscle (Weber et al. 1994). Tropomodulin consists of two 
structurally distinct regions: the N-terminal and the C-terminal domains. The N-terminal 
domain contains two tropomyosin-binding sites and one tropomyosin-dependent actin-binding 
site. The C-terminal domain contains a tropomyosin-independent actin-binding site (Colpan, 
Moroz & Kostyukova 2013). Two sarcomeric tropomodulin isoforms, Tmod1 and Tmod4, 
cap the pointed ends of the thin filaments and bind to the terminal tropomyosin. X-ray 
diffraction patterns were used to investigate single-membrane, permeabilised skeletal muscle 
fibres taken from mice lacking Tmod1. The absence of Tmod1 and its replacement by Tmod3 
and Tmod4 impairs initial tropomyosin movement over actin during thin-filament activation 
reducing both the fraction of actomyosin crossbridges in the strongly bound state and the 
fibre’s force-generating capacity. This shows that Tmods are novel regulators of actomyosin 
crossbridge formation and muscle contractility (Ochala et al. 2014).  
        Tropomodulin proteolysis and the resulting thin filament length misspecification 
contribute to the pathology of Duchenne muscular dystrophy, affecting muscles in a way 
which is both use- and disease severity–dependent (Gokhin et al. 2014). 
 
1.2.3.6 Leiomodin-3 
Leiomodins form a subfamily closely related to the tropomodulins (Conley et al. 2001).  
LMOD3 encodes leiomodin-3 (LMOD3), a 65-kDa protein expressed in skeletal and cardiac 
muscle. Resently the combination of whole-exome sequencing (WES) and Sanger sequencing 
identified homozygous or compound heterozygous variants in LMOD3 in 21 patients from 14 
families. They often had severe lethal form of NM. LMOD3 was expressed from early stages 
of muscle differentiation. It localized to actin thin filaments, with enrichment near the pointed 
ends and had strong actin filament-nucleating activity. Loss of LMOD3 in patient muscle 
resulted in shortening and disorganization of thin filaments. Knockdown of lmod3 in 
zebrafish replicated NM-associated functional and pathological phenotypes (Yuen et al. 
2014). 
 
1.2.3.7 The cofilins 
Two cofilins—cofilin 1 and cofilin 2—belong to the ADF/cofilin family that includes destrin, 
a closely related protein. The skeletal muscle isoform is encoded by the CFL-2 gene. 
ADF/cofilins and myosin-induced contractility are required in order to disassemble non-
productive filaments for the development of cardiomyocytes. Excess actin filaments are 
produced during sarcomere assembly and contractility is applied in the recognition of non-
productive filaments that are destined for depolymerisation. Thus, contractility-induced actin 
dynamics play an important role in sarcomere maturation (Skwarek-Maruszewska et al. 
2009).  
        Cofilin mutations have accompanied NM with minicores (Agrawal et al. 2007), 
including a combined case of NM and myofibrillar myopathy (Ockeloen et al. 2012). 
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1.2.4 Kelch domain– containing proteins  
In skeletal muscle development, kelch family members regulate the proliferation and 
differentiation processes resulting in the normal functioning of mature muscles. Many kelch 
proteins function as substrate-specific adaptors for Cullin E3 ubiquitin ligase, a core 
component of the ubiquitin-proteasome system which regulates protein turnover (Gupta and 
Beggs 2014). 
 
1.2.4.1 KBTBD13 
The protein KBTBD13 contains a BTB/POZ domain (BTB refers to Bric-a-brac, Tramtrack, 
Broad-complex; and POZ for Poxvirus and Zinc-finger) and five kelch- repeats and belongs 
to the superfamily of kelch-repeat–containing proteins. It is expressed primarily in skeletal 
and cardiac muscle. Previously identified BTB/POZ/kelch-domain–containing proteins have 
been implicated in a wide variety of biological processes, including cytoskeleton modulation, 
regulation of gene transcription, ubiquitination, and myofibril assembly (Sambuughin et al. 
2010, Prag and Adams 2003). 
        KBTBD13 on chromosome 15q22.31 when mutated causes NEM6. The clinical 
phenotype of patients includes poor exercise tolerance, characteristic but not consistent slow 
movements, an abnormal gait, and the development of slowly progressing muscle weakness 
of the neck and proximal limbs beginning in childhood. Dominant KBTBD13 mutations cause 
a histological picture of NM with cores and are located within conserved domains of kelch 
repeats. The mutations are predicted to disrupt the molecule's β-propeller blades (Sambuughin 
et al. 2010). 
 
1.2.4.2 KLHL40 
The sarcomeric protein KLHL40 belongs to the superfamily of kelch repeat–containing 
proteins. The kelch repeat is an evolutionarily widespread sequence motif of 44–56 amino 
acids. It occurs as five to seven repeats that form a β-propeller tertiary structure. The β-
propeller motif is primarily involved in protein–protein interactions, but performs a wide 
variety of other functions (Prag and Adams 2003). To date, 71 kelch repeat–containing 
proteins have been identified in humans. Confocal microscopy suggests that KLHL40 may 
localise to the sarcomeric A-band, a sarcomeric region not previously linked to NM 
(Ravenscroft et al. 2013b).  
        Mutations in KLHL40 causing a loss of function have been frequently associated with 
severe NM cases related to fetal akinesia sequence, a disease occurring globally. Functional 
studies revealed that KLHL40 is crucial to myogenesis and skeletal muscle maintenance 
(Ravenscroft et al. 2013b). 
 
1.2.4.3 KLHL41 
KLHL41 is a member of the BTB–kelch domain-containing family of proteins (Adams, Kelso 
& Cooley 2000). An exome-wide sequencing was performed, which identified small recessive 
deletions and missense changes in KLHL41 in four individuals from unrelated NM families. A 
clear genotype–phenotype correlation for the mutations was identified: frameshift mutations 
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resulted in severe phenotypes with neonatal death, whereas missense changes resulted in 
impaired motor functioning with patients living into late childhood and/or early adulthood. To 
evaluate the effects of the KLHL41 mutations on the protein structure, the mutations were 
mapped onto the crystal structures of the BTB–BACK domain of human KLHL11 protein and 
kelch domain rat KLHL41 protein analogous to those domains for human KLHL41 protein. 
Conservation of the mutated KLHL41 BTB–BACK and kelch domains and the potential role 
of the mutations in disrupting those structural domains support the likely pathogenicity of 
these mutations (Gupta et al. 2013). Analysis of transverse sections of myofibres revealed 
KLHL41 staining in a ring pattern around the myofibrils, colocalizing with the ryanodine 
receptors (RYR1). KLHL41 localises over (but not within) the I-bands, likely in association 
with the terminal cisternae of the sarcomplasmic reticulum (SR) and longitudinal vesicles of 
the SR present in the I-band area at the triadic regions (Gupta et al. 2013).  
 
1.2.4 The third filament: titin 
Titin is a giant filamentous protein and forms a separate myofilament system with calpain 3, 
myotilin and telethonin in both skeletal and cardiac muscle. This third filament system 
supports the contractile filaments during development. In mature cells, it provides mechanical 
support and possesses regulatory signalling functions (Bang et al. 2001, Gautel, Mues & 
Young 1999, Udd 2008). Titin is the third most abundant muscle protein after myosin and 
actin, with a molecular mass of 4200 kDa, representing the largest known polypeptide (Bang 
et al. 2001, Granzier and Labeit 2006). Titin spans 1 μm, extending halfway across the 
sarcomere. Its N-terminus is embedded in the Z disc and interacts with other Z-disc proteins. 
The titin I-band region is composed primarily of immunoglobulin (Ig) domains, the 
unstructured N2A and N2B region and the PEVK region (Gautel, Mues & Young 1999). The 
I-band region of titin contains multiple elastic spring elements that are responsible for the 
elastic properties of the titin filament system. Titin’s elastic spring supports ventricular filling 
during diastole in the heart muscle. Various splicing isoform variants exist in the I-band, 
which explains the titin size range from 27 000 to 33 000 residues in different striated muscle 
tissues (Bang et al. 2001, Improta, Politou & Pastore 1996). The titin A-band region is 
composed primarily of fibronectin type III-like and Ig domains, and has extensive interactions 
with myosin, myosin-binding protein C and other thick filament-associated proteins. The C-
terminus of titin is attached to the M-line and contains a kinase domain and Ig domains 
separated by unstructured M-insertions embedded in the M-line (Gautel, Mues & Young 
1999). Titins overlap in N- and C-termini and form a continuous filament system along the 
full length of the myofibril (Bang et al. 2001). In vitro binding studies revealed that the PEVK 
element of N2B titin binds F-actin. This dynamic interaction retards filament sliding. These 
kinds of interactions contribute to the passive stiffness of the sarcomere (Granzier and Labeit 
2002).  
Titin is encoded by a single gene located on the long arm of chromosome 2 in humans and 
mice. The genomic analysis of human titin revealed a 283-kb genomic segment that contains 
363 titin exons. These 363 exons have a coding capacity of 114 414 bp (4200 kDa) (Bang et 
al. 2001). Tibial muscular dystrophy is an autosomal-dominant late-onset distal myopathy 
caused by mutations in C-terminal titin (Hackman et al. 2002). In a homozygous form, the 
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mutation causes a more severe, recessive limb-girdle muscular dystrophy (Udd 2008). 
Mutations in titin also result in cardiomyopathy and dilated cardiomyopathy (van 
Spaendonck-Zwarts et al. 2014). Novel findings are titinopathies caused by recessive titin 
truncating mutations that define novel forms of core myopathy with heart disease (Chauveau 
et al. 2014). 
 
1.2.5 Muscle contraction 
The skeletal muscle contractile machinery is a system of interdigitating thick and thin 
filaments. The thick and thin filaments consist of a highly ordered assembly of proteins, with 
the thin filament acting as a major regulator of muscle contraction (Ochala 2008, Gordon, 
Homsher & Regnier 2000). The sliding filament theory, which was independently published 
in two articles in 1954 (Huxley and Niedergerke 1954, Huxley and Hanson 1954), describes a 
cycle of repetitive events that cause a thin filament to slide over a thick filament generating 
tension in a muscle. At rest, tropomyosin dimers lie along the actin filament in a potential 
myosin-binding site, sterically inhibiting myosin–actin interactions. When muscle is 
stimulated, intracellular calcium levels increase to a critical level. This releases the inhibitory 
effect of troponin so that tropomyosin moves into the groove between actin helices revealing 
the myosin-binding sites and triggering muscle contraction (Gordon, Homsher & Regnier 
2000). 
 
1.2.5.1 Protein interactions  
In a current model for contraction regulation, three states existing in equilibrium have been 
proposed: blocked, closed and open (McKillop and Geeves 1993, Tobacman 1996, Craig and 
Lehman 2001, Hai et al. 2002). Calcium and myosin control the transition between states. In 
the absence of Ca
2+
, contraction is blocked (blocked state). Tropomyosin sterically hinders 
interactions between actin and the myosin S1 fragment and the weak electrostatic binding of 
myosin to the actin binding sites is blocked at actin by troponin I. In the presence of Ca
2+
, the 
conformation of the troponins change. Ca
2+
 binds to troponin C and initiates changes in the 
troponin C–troponin I interactions. The inhibitory binding of troponin I to tropomyosin and 
actin is relieved. Tropomyosin moves across the surface of actin and can only bind myosin S1 
relatively weakly (closed state) exposing myosin-binding sites on actin. Myosin S1 can both 
bind to actin, resulting in the release of ADP, and inorganic phosphate, and form crossbridges 
and undergo an isomerisation to a more strongly bound, rigor-like conformation. Weak to 
strong binding of myosin to actin causes a further movement of tropomyosin across the 
surface of actin (open state). New myosin-binding sites on actin are exposed, permitting the 
formation of further crossbridges allowing for the production of force and motion (Ochala 
2008, Gordon, Homsher & Regnier 2000, McKillop and Geeves 1993). Nebulin contributes to 
the regulation of crossbridge cycling kinetics, increasing the force and efficiency of 
contraction, and plays a role in the calcium sensitivity of force generation (Chandra et al. 
2009) (Figure 4). 
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Figure 4. Calcium binds to troponin C present on the actin-containing thin filaments of the 
myofibrils. Troponin then allosterically modulates tropomyosin. Under normal circumstances, 
tropomyosin sterically obstructs binding sites for myosin on the thin filament; once calcium 
binds to troponin C and causes an allosteric change in the troponin protein, troponin T allows 
tropomyosin to move, unblocking the binding sites.  
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1.2.5.2 Excitation–contraction coupling 
The term excitation–contraction coupling, coined in 1952, describes events occurring when a 
stimulus is applied to muscle. The response to a stimulus is indicated first by excitation, 
which is set up in the membrane of each reacting muscle fibre, and then by contraction, which 
is a function of the substance within the membrane (Sandow 1952). Excitation–contraction 
(EC) coupling in skeletal muscle is dependent on a physical interaction between the skeletal 
isoforms of the dihydropyridine receptor L-type Ca
2+
 channel (DHPR) and the ryanodine 
receptor Ca
2+
 release channel (RyR1). RyR1 channels release Ca
2+
 from the sarcoplasmic 
reticulum calcium stores into the cytoplasm to mediate muscle contraction in response to 
signals from voltage-sensitive surface membrane channels. An important part of EC includes 
the proper structure of the muscle membranes. The plasma membranes come into very close 
association with the membranes of the internal sarcoplasmic reticulum (SR) Ca
2+
 store. In 
functional coupling regions, the junctional gap between the surface and SR membranes is 
only ∼10-nm wide. This allows the cytoplasmic domains of proteins in the membrane on 
either side of the junction to come into such close contact that they can interact with each 
other. In adult skeletal muscle, the junctions, also known as triads, have terminal expansion of 
SR on either side of a central transverse t-tubule element (Rebbeck et al. 2014). The clusters 
of four αS1 voltage sensor particles, termed tetrads, are situated in the junctional regions of the 
surface membrane. The αS1 particles within the tetrad are positioned in such a way that they 
respond to the four subunits of RyR1 situated in the underlying SR membrane. The term 
couplon describes the generic surface/SR junction containing the functional groupings of 
proteins that facilitate EC coupling (Franzini-Armstrong 1999). DHPR works as a voltage 
sensor for EC coupling and sends a signal to RyR in response to surface membrane 
depolarisation and the signal results in the release of Ca
2+
 from SR. This interaction between 
DHPR and RyR in EC coupling enables all voluntary movement, respiration and cardiac 
contraction. Correct interactions between DHPR and RyR are, thus, essential for life. Defects 
in the expression or function of either protein result in poor development in utero and death at 
or before birth. Mutations in the proteins lead to a susceptibility to malignant hyperthermia, 
central core disease and cardiac arrhythmias (Dulhunty et al. 2002). 
 
 
2 Congenital myopathies    
The term congenital myopathies designates a group of congenital muscle disorders defined on 
the basis of structural abnormalities of the muscle fibres which are visible after staining 
muscle biopsy sections using histochemical methods (Jungbluth and Wallgren-Pettersson 
2013). Congenital myopathies include a spectrum of clinically, histologically and genetically 
variable neuromuscular disorders, many of which are caused by mutations in the genes for 
sarcomeric proteins (Wallgren-Pettersson et al. 2011). Classified mainly on the basis of their 
histopathology, they share many clinical features, including hypotonia and generalised often 
non-progressive muscle weakness which is often present at birth. The severity of weakness 
and disability varies widely: from neonates with a profound generalised weakness to patients 
with weakness that first manifests during childhood through delayed motorskill milestones or 
later in life through proximal weakness (Sewry 2008, Nance et al. 2012, North et al. 2014). In 
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congenital myopathies, electromyography (EMG) is typically normal or shows myopathic 
features. Occasionally changes that appear neurogenic are visible with severe neonatal 
weakness or in distal muscles as the disease progresses (Wallgren-Pettersson, Sainio & Salmi 
1989). Serum creatine kinase levels are usually within normal limits, but may be mildly to 
moderately higher than normal. Genetically distinct congenital myopathies may overlap in 
their pathology, making the precise diagnosis challenging in individual cases and suggesting 
that shared pathogenetic mechanisms between congenital myopathies exist (Sewry 2008, 
Nance et al. 2012, North et al. 2014). Four main categories distinguish classical congenital 
myopathies based on the histology: nemaline myopathies, central core disease, multi-minicore 
disease and centronuclear myopathies (Nance et al. 2012). NM is the most common 
congenital myopathy occurring at a rate of 0.02/1000 live births (Wallgren-Pettersson et al. 
2011). Findings suggest that the genes for classical congenital myopathies may also cause 
other myopathies, including cap myopathy (Fidzianska et al. 1981, Schröder 1982), 
congenital fibre-type disproportion (Brooke 1973), myotubular myopathy (Laporte et al. 
1996), central core myopathy (Shy and Magee 1956) and multi-minicore myopathy (Ferreiro 
et al. 2002) which is often caused by defects in the thin filament proteins. Some forms of 
distal arthrogryposis (DA), which is also related to defects in the thin filaments (Daentl et al. 
1974, Krakowiak et al. 1997), are characterised by congenital contractures. The clinical 
severity ranges from severe and fatal perinatal disease to forms that are milder and manifest 
later in childhood (Lawlor and Beggs 2013). The focus of the present study is nemaline 
myopathy and the genetically related disorders of cap myopathy, congenital fibre-type 
disproportion and distal arthrogryposis. 
 
 
2.1 Nemaline myopathies  
 
2.1.1 Nemaline myopathy 
A new congenital myopathy was first described in 1963 by two groups (Shy et al. 1963, 
Conen, Murphy & Donohue 1963), and was given the name NM by Shy et al. in 1963 since 
the rods of fibrous structures were found in the muscle biopsy of a 4-year-old child with non-
progressive proximal muscle weakness (Greek nema, thread) (Shy et al. 1963). Conen and co-
workers, carrying out microscopic studies in a child with hypotonia and muscle weakness, 
described the same disease (Conen, Murphy & Donohue 1963). NM is characterised by 
muscle weakness and the presence of nemaline (rod) bodies in the muscle fibres. These rods 
are composed of thin filament and Z-disc proteins (Jockusch et al. 1980, Schroder et al. 2003, 
Wallgren-Pettersson, Arjomaa & Holmberg 1990, Vainzof et al. 2002). Muscle weakness in 
NM is usually generalised, but a selective pattern of more pronounced weakness may also 
occur, including respiratory muscles weakness (Wallgren-Pettersson et al. 2004). The clinical 
spectrum of NM is wide, ranging from severe to mild. The term typical NM generally applies 
to the group of congenital nemaline myopathies that present with early hypotonia and muscle 
weakness. Reports also include adult-onset cases (Wallgren-Pettersson et al. 2011, Wallgren-
Pettersson et al. 2004).  
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        The European Neuromuscular Centre International Consortium on NM set the criteria for 
six clinical categories of NM: (1) the severe congenital form when patients lack spontaneous 
movement or respiration at birth or accompanied by fractures or severe contractures at birth 
(NM1); (2) the intermediate congenital form when patients move and breath at birth but are 
later unable to achieve ambulation or respiratory independence (NM2); (3) the typical 
congenital form accompanied by a typical distribution of muscle weakness, delayed 
milestones which are eventually reached and a slowly progressive or non-progressive course 
(NM3); (4) mild NM with childhood onset (NM4); (5) adult-onset NM (NM5); and (6) other 
forms of NM accompanied by unusual associated features (NM6) (Wallgren-Pettersson and 
Laing 2000, Wallgren-Pettersson et al. 2011). 
        Related myopathies include cap myopathy (Fidzianska et al. 1981, Schröder 1982), distal 
myopathy without or with nemaline bodies (Wallgren-Pettersson et al. 2007, Lehtokari et al. 
2011), core-rod myopathy with generalised or distal weakness (von der Hagen et al. 2008, 
Romero et al. 2009), intranuclear rod myopathy and congenital fibre-type disproportion 
(Brooke 1973). Myotubular myopathy (Laporte et al. 1996), central core myopathy (Shy and 
Magee 1956) and multi-minicore myopathy are regarded as distinct congenital myopathies 
(Ferreiro et al. 2002).  
 
2.1.1.1 Molecular genetics of nemaline myopathy  
All molecularly characterised forms of NM are autosomal. Inheritance can be recessive or 
dominant with singleton cases arising from de novo dominant mutations (Wallgren-Pettersson 
et al. 2011). Nine different causative genes have been identified for NM: nebulin (NEB), slow 
skeletal muscle -actin (ACTA1), -tropomyosin (TPM2), slow -tropomyosin (TPM3), slow 
troponin T (TNNT), cofilin 2 (CFL2), a member of the BTB/kelch protein family (KBTBD13) 
and kelch-like family members 40 and 41 (KLHL40 and KLHL41) (Laing et al. 1995, Pelin et 
al. 1999, Nowak et al. 1999, Johnston et al. 2000, Donner et al. 2002, Agrawal et al. 2007, 
Sambuughin et al. 2010, Ravenscroft et al. 2013b, Gupta et al. 2013). All of the causative 
genes result in diseases that may have different characteristics, which is shown by the 
classification of NM into different categories from NEM1–NEM7. TPM3 causes NEM1, NEB 
NEM2, ACTA1 NEM3, TPM2 NEM4, TNNT1 NEM5, KBTBD13 NEM6 and CFL2 NEM7. 
The newly identified KLHL40 and KLHL41 have yet to be assigned NEM numbers. 
        Mutations in nebulin and ACTA1 are the most common causes of NM (Wallgren-
Pettersson et al. 2007). Nebulin mutations are thought to account for roughly 50% of cases 
(Lawlor et al. 2011). The most common causes of NM are recessive mutations in nebulin and 
de novo dominant mutations in ACTA1. At least one further gene remains unidentified based 
on analyses of linkage results (Wallgren-Pettersson et al. 2011). Six of the nine known genes 
encode proteins of, or closely associated with, the thin filaments of the sarcomere. The 
function of the protein product of KBTBD13 is not yet known (Sambuughin et al. 2010). 
Significant histopathological overlap with defects in the same gene resulting in different 
pathologies and defects in different genes resulting in the same pathology exist (Wallgren-
Pettersson et al. 2011).  
        In nebulin, 211 mutations have been identified to date. These mutations are recessive and 
patients are usually compound heterozygous. Most of the mutations are frameshift or 
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nonsense mutations, but missense mutations, point mutations and deletions also occur (Pelin 
et al. 1999, Lehtokari et al. 2006). An in-frame deletion of exon 55 was found in the 
Ashkenazi Jewish population (Anderson et al. 2004). Similarly, more than 200 different 
ACTA1 mutations have been identified, the majority of which cause NM or NM with 
associated features such as cores, actin aggregates or intranuclear rods. Most are dominant 
missense mutations and arising de novo, while about 10% of the mutations are recessive. 
Dominant inheritance is less common and only seen in families with a milder phenotype 
(Laing et al. 2009). In TPM2, two heterozygous, dominant missense mutations causing NM 
are known (Donner et al. 2002). Additionally, individual cases have included a homozygous 
null mutation in a patient with NM and Escobar syndrome (Monnier et al. 2009) as well as a 
dominant heterozygous mutation in a mother with NM and her cap myopathic daughter 
(Tajsharghi et al. 2007a). The mutations in TPM3 are most often dominant, missense 
mutations, while some recessive mutations have been described (Nowak et al. 2012). A 
recessive deletion occurs as a founder mutation in the Turkish population (Lehtokari et al. 
2008). A TNNT1 recessive nonsense founder mutation is present in the Old Order Amish 
population producing characteristic progressive NM with tremors and contractures (Johnston 
et al. 2000). Recently, a patient who is compound heterozygous for a c.309+1G>A mutation 
and an exon 14 deletion in the TNNT1 gene was found outside the Old Order Amish (van der 
Pol et al. 2014). A few studies identified homozygous missense mutations and other variants 
in the CFL2 gene (Agrawal et al. 2007, Ockeloen et al. 2012, Ong et al. 2014). Three 
dominant missense mutations were found in KBTBD13, but not all mutation carriers in the 
families showed skeletal muscle weakness (Sambuughin et al. 2010). KLHL40 mutations 
resulting in a very severe autosomal-recessive NM were identified as the most common cause 
of this severe form of NM. KLHL40 plays a key role in muscle development and function. 
The clinical features of affected infants included fetal akinesia or hypokinesia and 
contractures, fractures, respiratory failure and difficulties swallowing at birth (Ravenscroft et 
al. 2013b). Mutations in KLHL41 were recently found to cause NM. Five mutations were 
identified, including missense changes, insertion, deletion and frameshift mutations. They 
showed clear phenotype–genotype correlations: frameshift mutations caused severe 
phenotypes with neonatal death, whereas missense changes resulted in impaired motor 
function and survival into late childhood and/or early adulthood (Gupta et al. 2013). 
 
2.1.1.2 Clinical pictures of NM  
The spectrum of NM varies clinically from fetal akinesia to mild childhood-onset forms, as 
well as adult-onset cases which may not be genetic in origin (Wallgren-Pettersson et al. 
2004). Patients with typical NEB-caused NM normally experience congenital generalised 
muscle weakness and hypotonia. In the typical form of NM, muscle weakness is usually 
generalised and symmetric with a predilection for neck flexors sparing the extraocular 
muscles. It is clinically important to note a greater weakness in the respiratory muscles than 
that of other muscle groups, which leads to often unsuspected slowly emerging hypoxia. 
Cardiac contractility is normal with rare exceptions. Distal forms and forms with weakness 
only in the lower limbs may also occur (Wallgren-Pettersson et al. 2004). Newborns 
experience frequent feeding and breathing problems. Facial and neck flexor weakness are 
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common features and mild contractures may be present. Early proximal weakness may be 
combined with distal weakness later in life. The severe form of NM may present before birth 
with polyhydramnios and weak fetal movement, which may be accompanied by congenital 
arthrogryposis and/or fractures. In mild forms of NM, patients present with delayed motorskill 
milestones or respiratory complications and a delayed onset of disease (Jungbluth and 
Wallgren-Pettersson 2013, Wallgren-Pettersson, Kalimo & Lammens 2013). A recessive form 
of NM is caused by a mutation to TNNT1 in children from the Old Order Amish community. 
This NM is characterised by a tremor and contractures, and runs a progressive course 
(Johnston et al. 2000). The sporadic late-onset form of NM includes subacute onset after the 
third decade of life and is often autoimmune in origin (Chahin, Selcen & Engel 2005). 
 
2.1.1.2.1 NM caused by nebulin and tropomyosins  
NM caused by mutations in the nebulin gene NEM2 are known to cause severe, intermediate, 
mild, typical and other forms of NM. The typical form of NM occurs most frequently. All 
mutations identified in this gene have thus far been recessive (Wallgren-Pettersson et al. 
2011). The typical form of NM is characterised by an initial predominantly proximal pattern 
of muscle weakness, more pronounced in the axial muscles and the limb girdles than in the 
proximal limb muscles. Distal involvement and proximal muscle weakness including foot 
drop is usually noted later (Wallgren-Pettersson et al. 2011).  
        Dominant mutations in the slow α-tropomyosin gene TPM3 may cause the mild form of 
NM, NEM1, whereas the more rare recessive TPM3 mutations cause the intermediate form of 
NM, NEM2 (Tan et al. 1999). In patients with TPM3 mutations, fibre-type distribution is 
variable, but nemaline bodies are often only present in type-1 fibres which are small 
(Wallgren-Pettersson et al. 2011). A founder mutation has been identified in the Turkish 
population for TPM3 (Lehtokari et al. 2008). 
        NM caused by mutations in the β-tropomyosin gene TPM2, NEM4, present with the mild 
or typical form of disease. Biopsies show marked hypotrophy or atrophy of type-1 fibres 
(Lawlor and Beggs 2013). A clinical and histological overlap between these disorders exists, 
such that they may form parts of a spectrum rather than distinct entities (Wallgren-Pettersson 
et al. 2011).  
.  
2.1.2 Distal nemaline myopathy 
Distal myopathies are a clinically and genetically heterogeneous group of muscle disorders 
characterised by predominantly distal muscle weakness. Two families were identified with 
distal myopathy caused by mutations in nebulin and characterised by the early onset of 
predominantly distal muscle weakness and wasting combined with abundant nemaline bodies 
in the muscle fibres. The distal onset distinguished this from the typical form of NM, while 
the disease characteristics—the predominance of distal involvement later in the disease 
progression, the severe fatty replacement in the tibialis anterior and the preservation of the 
tibialis posterior muscles—are similar to typical NM caused by nebulin mutations. Thus, NM 
and distal myopathy caused by nebulin mutations form a clinical and histological continuum 
(Lehtokari et al. 2011).  
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2.1.3 Distal nebulin myopathy 
Distal nebulin myopathy with childhood- or adult-onset foot drop was caused by two 
homozygous missense mutations in nebulin in Finnish families (Wallgren-Pettersson et al. 
2007). The ankle dorsiflexors, the finger extensors and the neck flexors are primarily affected. 
Distal nebulin myopathy differs histologically from NM in that no detectable nemaline bodies 
are seen under light microscopy and are absent or vague under electron microscopy. In 
contrast to most other distal myopathies, no rimmed vacuoles are present (Pelin and 
Wallgren-Pettersson 2008).  
 
2.1.1.3 Muscle pathology of nemaline myopathy 
The most prominent histopathological feature in NM is the presence of nemaline bodies in the 
muscle fibres. Modified Gömöri trichrome staining (Lake, Wilson 1975) of frozen sections of 
muscle biopsies is routinely used to visualize nemaline bodies (Figure 5). They appear as red-
coloured rods in clusters or sometimes individually in the centre or periphery of muscle 
fibres. In some cases, the staining of plastic sections with toluidine blue or electron 
microscopy is required to visualise the nemaline bodies if only a few are present or they are 
very small (Wallgren-Pettersson et al. 2011). Rods are often seen in all fibre types and type-1 
fibre predominance is common. α-Actinin is the main component of the rods (Jockusch et al. 
1980), but tropomyosin, actin, myotilin, nebulin and desmin are also present on the surface of 
the rods in smaller quantities (Schroder et al. 2003, Yamaguchi et al. 1982).  
        Nemaline bodies appear under electron microscopy as electron-dense structures, which 
are rod-shaped or ovoid and resemble thickened or elongated Z-discs. Rods are often found in 
clusters but may also be isolated. The proportion of the affected fibres may vary greatly 
between different muscles and may change with age (Wallgren-Pettersson et al. 2011); no 
correlation has been found between muscle weakness and the quantity of nemaline bodies 
(Ilkovski et al. 2001, Ryan et al. 2003). NM caused by nebulin mutations may show fibre 
splitting, internal nuclei, fatty infiltration and fibrosis in later stages of disease (Wallgren-
Pettersson, Rapola & Donner 1988). 
 21 
 
 
 
Figure 5. Histology of NM, cap myopathy and congenital fibre-type disproportion (CFTD). 
The range of abnormalities in skeletal muscle that can arise with mutations in tropomyosin is 
shown in these images. A–C: Nemaline myopathy (NM). In TPM2 NM (A, p.K7del 
mutation), rods are often randomly scattered. In TPM3 NM (B, p.M9R), rods are confined to 
type-1 fibres, which are usually hypotrophic. C: Nemaline bodies under electron microscopy. 
D–F: CFTD due to mutations in TPM3. D–E: ATPase (4.3) showing a consistent difference in 
size between type-1 fibres (dark) and type-2 fibres (pale). Type-1 fibre predominance is 
common (D), but a range is observable (E). D: Increased internalised nuclei in large (type-2) 
fibres in an adult CFTD patient with the TPM3 p.L100M mutation. G–J: Cap myopathy due 
to the TPM2 p.Glu139del mutation. On light microscopy, caps are most commonly seen on 
ATPase stains (H), but may also be visible on H&E stains (G) or oxidative stains. I–J: 
Electron microscopy of a typical cap structure. Modified from Marttila et al. Hum Mutat. 
2014 35(7):779–90 with permission from Wiley.  
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2.1.1.3 Pathogenesis of nemaline myopathy 
NM was thought of as a disorder of the thin filament proteins. The recently discovered 
mutations in genes that do not encode thin filament proteins, however, has challenged this 
model (Gupta et al. 2013). To understand the pathogenetic mechanisms underlying NM, it is 
necessary to unravel the normal interactions of the proteins involved in the disease. Mutations 
in the genes encoding parts of the thin filament may disrupt the ordered assembly of 
sarcomeric proteins. The interactions between the thin and thick filaments during muscle 
contraction may also be disturbed (Gupta et al. 2013, North and Ryan 1993–2014). The 
unifying pathogenetic mechanism in NM is thought to result in reduced force generation due 
to the impaired thin filament function (Ochala 2008). 
 
2.1.1.3.1 Studies of individual genes and their mutations 
Studies of ACTA1 mutations in tissue cultures demonstrate that some mutant actins carry a 
dominant negative effect on thin filament assembly and function. The mutations in ACTA1 
cause abnormal folding, altered polymerisation and aggregation of mutant actin isoforms. The 
effects are mutation-specific and may cause variations in the severity of muscle weakness 
seen in individuals (Ilkovski et al. 2004). ACTA1 mutation p.Asp286Gly studies on the 
mechanics of membrane-permeabilised single-muscle fibres and molecular energy-state 
computations demonstrated that, during contraction, the Asp286Gly acts as a ‘poison protein’ 
and modifies the actin–actin interface. This likely prevents proper myosin crossbridge 
binding, limiting the fraction of actomyosin interactions in the strong binding state, thus 
decreasing the force-generating capacity at the cell level, thereby inducing muscle weakness 
(Ochala et al. 2012a). 
        The mechanisms underlying the impaired muscle function in patients with a TPM2 
p.Arg133Trp mutation were investigated measuring the maximum force normalised to a fibre 
cross-sectional area, the maximum velocity of unloaded shortening, the apparent rate constant 
of force redevelopment and the force–pCa relationship. The results indicated a slower 
crossbridge attachment rate and a faster detachment rate caused by the TPM2 p.Arg133Trp 
mutation. The mutation induces an alteration in myosin–actin kinetics causing a reduced 
number of myosin molecules in the strong actin-binding state, resulting in overall muscle 
weakness (Ochala et al. 2007). The various tropomyosin mutations induce a thin filament 
dysfunction via distinct physiological mechanisms. Two divergent, mutation-specific 
pathophysiological mechanisms were found among three tropomyosin mutants. The TPM2-
null and TPM3 p.Arg167His mutations both decreased cooperative thin filament activation 
and reduced the number of myosin crossbridges and the force production. The TPM3 
p.Arg167His mutation also caused a reduction in the thin filament length. In contrast to other 
mutations, the TPM2 p.E181Lys mutation increased the thin filament activation, crossbridge 
binding and force generation (Ochala et al. 2012b).   
        Studies of the contractile phenotypes of NM patients with nebulin mutations causing 
NM2 revealed markedly lower nebulin protein abundance in the muscle, but the levels of 
other thin filament–based proteins did not significantly alter. A reduced Ca2+ sensitivity in the 
force generation in NM muscle fibres existed compared to the control fibres and a slower rate 
constant of force redevelopment and an increased tension cost in NM was found compared to 
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the control fibres. Thus, in NM muscle, the rate of crossbridge attachment decreases and the 
rate of crossbridge detachment increases (Ottenheijm et al. 2010). Some mutations in nebulin 
caused abnormal NEB expression and impaired muscle force generation in severe NM 
(Lawlor et al. 2011).  
        Molecular modelling of KLHL40 revealed that all of the substituted residues are involved 
in intramolecular interactions. The substitutions may destabilise the hydrophobic cores of the 
BTB–BACK domain. Modelling and free-energy calculations suggest that most KLHL40 
missense mutations impair protein stability (Ravenscroft et al. 2013b). Functional studies in a 
zebrafish model revealed that the loss of KLHL41 results in extensive skeletal muscle 
disorganisation associated with sarcomeric abnormalities, which points towards a KLHL41 
function in skeletal muscle development and maintenance (Gupta et al. 2013).  
        Together, these effects contribute to the common pathologic hallmarks of NM, such as 
rod formation, the accumulation of thin filaments and myofibrillar disorganisation. 
 
2.1.1.4 Animal models of nemaline myopathy 
Animal models, particularly those for mice and zebrafish, proved useful in elucidating the 
pathogenetic mechanisms associated with congenital myopathies, as well as providing models 
in which future therapeutic options may be investigated (Nance et al. 2012). To investigate 
the functional role of nebulin in vivo, nebulin-deficient mice were generated using a Cre 
knock-in strategy (Bang et al. 2006) and through targeted gene disruption (Witt et al. 2006). 
NEB-null mice were born in Mendelian ratios with a normal body weight compared with wt 
littermates (Bang et al. 2006, Witt et al. 2006). NEB-null mice barely increased in weight after 
birth, possessed little subcutaneous fat and died 8–11 days after birth (Bang et al. 2006). 
Nebulin knock-out mice created using targeted gene disruption in embryonic stemcells (ES) 
were viable up to day 20 postnatal (Witt et al. 2006). The diaphragm muscles of NEB-null 
mice featured well-aligned sarcomeres with the same appearance as wt muscles at embryonic 
day 18.5. At day 9 postnatal, NEB-null mice diaphragm muscles showed a severe disruption 
of the myofibrillar structure, including a lack of well-defined A- and I-bands (Bang et al. 
2006). A third knock-out mouse model was created with nebulin exon 55 deleted in order to 
replicate a founder mutation seen frequently in patients with NM from the Ashkenazi Jewish 
community. These mice showed growth retardation after birth. Nemaline bodies and reduced 
nebulin levels were apparent in the muscle fibres and the thin filament length was 
significantly shorter than in wt mice (Ottenheijm et al. 2013). The muscles worked beyond 
their optimal length range, which caused an incomplete overlap of the thick and thin 
filaments, resulting in instability and damage to the filaments (Morgan and Allen 1999). NEB-
null mice also showed shorter thin filament lengths (Bang et al. 2006, Witt et al. 2006, 
Ottenheijm et al. 2013). This resulted in impaired muscle contraction and force generation 
shown by marked changes in the crossbridge cycling kinetics and through a reduction in the 
calcium sensitivity of force generation, one of the pathogenetic mechanisms leading to muscle 
weakness in NM patients (Ottenheijm et al. 2013).  
        Mouse models of NM exist which also contain TPM3 mutations (Corbett et al. 2001). 
Muscle weakness was evident in the mice at 5–6 months of age, mimicking the late onset of 
NM observed in humans with a p.Met9Arg mutation in TPM3 (Corbett et al. 2001). To 
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determine the mutant ACTA1 pathobiology, ACTA1(D286G) transgenic mice were 
engineered. The mice were less active than wt individuals, their skeletal muscles were 
significantly weaker by in vitro analyses and they showed various pathological lesions 
reminiscent of human patients; but, they had a normal lifespan. ACTA1
D286G + / +
 mice 
presented with severe immobility between days 8 and 17 postnatal. The mutant protein load 
determined the severity of ACTA1 disease (Ravenscroft et al. 2011a). Cardiac α-actin can 
substitute for skeletal muscle α-actin, preventing early postnatal death of ACTA1 knock-out 
(KO) mice. In one model, investigation of the transgenic overexpression of cardiac α-actin in 
postnatal skeletal muscle showed that the lethality of ACTA1D286G in mice decreased from 
∼59% to ∼12% before reaching 30 days old. In another model, ACTA1H40Y, for which 
∼80% of male mice die by 5 months of age, the cardiac α-actin transgene did not significantly 
improve survival. Thus, cardiac α-actin overexpression is a likely therpy for at least some 
dominant ACTA1 mutations (Ravenscroft et al. 2013a). Mechanical and X-ray diffraction 
pattern analyses of single-membrane permeabilised myofibres show, at maximal Ca
2+
 
activation and under rigorous conditions, less stiffness and disruption of actin-layer line 
reflections in ACTC
Co
/KO was found when compared with age-matched wt mice. These 
results show that, in ACTC
Co/KO myofibres, the presence of cardiac α-actin instead of 
skeletal muscle α-actin alters the actin conformational changes upon activation, modulating 
individual actomyosin interactions and lessening the myofibre force production. This has 
influenced the design of gene therapies for ACTA1-based congenital myopathies (Ochala et al. 
2013b). 
        Similarly, a zebrafish model for NM was developed which harbours a recessive mutation 
in nebulin resulting in decreased NEB protein levels, a severe motor phenotype and premature 
lethality. In addition, many of the features associated with human NM were present, including 
impaired force generation, altered thin filament length and the formation of nemaline bodies 
(Telfer et al. 2012). Zebrafish models of NM KLHL40 isoforms a and b showed that their 
expression is largely confined to the myotome and skeletal muscle, and the knockdown of 
these isoforms results in the disruption of muscle structures and the loss of movement. 
Electron-microscopic analysis showed disarranged myofibrils with widened Z-discs 
(Ravenscroft et al. 2013b). Functional studies in a zebrafish model with the loss of the 
KLHL41 gene resulted in highly reduced motor function and myofibrillar disorganisation 
accompanied by nemaline body formation (Gupta et al. 2013).  
 
 
2.2 Disorders related to nemaline myopathy 
 
2.2.1 Cap myopathy 
Cap myopathy or cap disease was first described in 1981 by Fidzianska and co-workers 
(Fidzianska et al. 1981), while Schröder reported a case of ‘myopathy with subsarcolemmal-
segmental myofibrillolysis’ in 1982 (Schröder 1982). The name derives from the cap-like 
structures located under the sarcolemma. Patients exhibit muscle hypotonia, weakness, 
skeletal dysmorphism and respiratory insufficiency beginning in childhood, and their muscles 
contain abnormally structured muscle fibres. The pathognomonic peripherally located cap 
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structures lack ATPase and fast myosin activity and are rich in desmin, tropomyosin and α-
actinin, and consist of abnormally arranged myofibrils. The peripheral position of myofibrils 
and their abnormal sarcomere pattern point to an error in fusion and muscle protein synthesis 
(Fidzianska 2002). 
 
2.2.1.1 Molecular genetics of cap myopathy 
The first genetic causes of cap disease were identified in 2007 in the gene coding for β-
tropomyosin (TPM2), specifically a deletion of glutamic acid at position 139 (Lehtokari et al. 
2007) and a change at position 41 of glutamate to lysine (Tajsharghi et al. 2007b). Since then, 
genetic analyses have revealed three causative genes for cap myopathy: ACTA1 encoding 
slow skeletal muscle α-actin (Hung et al. 2010), TPM2 encodes β-tropomyosin and TPM3 
encodes α-tropomyosin in slow muscle fibres (De Paula et al. 2009). Cap myopathy is, in 
most cases, caused by de novo dominant mutations with no family history (Schreckenbach et 
al. 2014). The ACTA1, TPM2 and TPM3 genes encode the thin filament proteins that are 
components of the contractile apparatus. TPM2 is expressed in both slow, and, to a lesser 
extent, in fast muscle fibres. TPM3 is expressed exclusively in slow muscle fibres (Perry 
2001). 
 
2.2.1.2 Clinical picture of cap myopathy   
The clinical features of cap myopathy include onset in infancy or childhood, delayed 
motorskills milestones, primarily proximal and axial muscle weakness, a long myopathic face 
with a high-arched palate, skeletal deformities such as scoliosis, an elongated face, a high-
arched palate and respiratory problems leaving some patients reliant upon ventilatory support. 
Severe cardiac involvement is not a common feature of cap myopathy, reported in only a few 
cases (Schreckenbach et al. 2014, Clarke et al. 2009). In most cap myopathy patients, the 
creatine kinase level in serum is normal and EMG usually displays a myopathic pattern 
(Schreckenbach et al. 2014), similar to the case for other NM-related disorders and congenital 
myopathies in general. 
 
2.2.1.3 Muscle pathology of cap myopathy 
The caps are peripherally located, sharply demarcated inclusions located under the 
sarcolemma (Figure 4), appearing purple-bluish or greenish under modified Gömöri trichrome 
staining and eosinophilic under hematoxylin and eosin staining. In nicotinamide adenine 
dinucleotide-tetrazolium reductase (NADH-TR) staining, the caps show a dark-bluish 
reactivity, but the myosin ATPase reaction is weak. The caps contain disorganised thin 
filaments and Z-disc material. The caps are composed of α-actinin, actin, troponin T, 
sarcomeric tropomyosin and desmin as revealed by immunohistochemistry. In some cases, 
thickened Z-lines appearing as rod-like structures are observed within the caps. The 
proportion of caps ranges from 4% to nearly 100% of muscle fibres and correlates with the 
disease severity and the patient’s age (Schreckenbach et al. 2014). In the presense of cap 
structures, a lack of thick filaments is observed, while the preservation of thin filaments in the 
sarcomere and prominent Z-discs suggest a defect in myosin synthesis (Fidzianska 2002).  
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2.2.2 Congenital fibre-type disproportion 
The term CFTD was used for the first time by Brooke in 1973 for patients with a fibre-size 
disproportion (FSD) of 12% or more (Brooke 1973). The main histologic abnormality in this 
congenital myopathy is defined by type-1 fibres that are consistently smaller than type-2 
fibres. Brooke (1973) suggested defining the group of patients with FSD but no other 
significant histologic abnormalities would be useful. Since then, minor degrees of FSD have 
been described in many conditions, including disorders of the central and peripheral nervous 
systems, metabolic disorders and muscular dystrophy. CFTD is a congenital myopathy that 
may be best viewed as a syndrome rather than as a formal diagnosis (Clarke 2011b). 
Diagnosis must be carefully made since this histologic abnormality may occur in other 
congenital myopathies and in other neuromuscular disorders (Clarke 2011a). Often, a second 
biopsy reveals pathognomonic findings for one of the more well-defined myopathies 
(Jungbluth and Wallgren-Pettersson 2013).  
 
2.2.2.1 Molecular genetics of congenital fibre-type disproportion 
The causes of CFTD without specific histological features are mutations in the TPM3 (Clarke 
et al. 2008, Schessl et al. 2008), RYR1 (Clarke et al. 2010) and ACTA1 (Laing et al. 2004) 
genes, while all NM genes are known to cause FSD. Mutations in the MYH7 (Ortolano et al. 
2011) or TPM2 genes (Brandis, Aronica & Goebel 2008) and the gene causing an X-linked 
form of (Clarke et al. 2005) CFTD appear to be rare. Mutations in TPM3 were first identified 
in patients with NM (Laing et al. 1995), but it now appears that CFTD without nemaline 
bodies is the histologic finding most often associated with mutations in TPM3. Most TPM3 
mutations associated with CFTD are dominant missense changes. Patients generally present 
with mild to moderate muscle weakness and retain the ability to walk into adulthood (Clarke 
2011a). The severity of disease caused by RYR1 mutations vary from death due to respiratory 
failure in the neonatal period to difficulties climbing stairs in the late teen years. Patients 
experienced hypotonia and weakness of the axial muscles, and when generalised weakness 
was marked, myopathic facies, respiratory failure and feeding difficulties were present 
(Clarke et al. 2010). NM is commonly associated with mutations in ACTA1 (Laing et al. 
2009). As a cause of CFTD, mutations in ACTA1 appear to be uncommon, accounting for 
approximately 5% of patients (Laing et al. 2004). Normally, stable, generalised and often 
severe weakness follows the pattern described in other ACTA1 myopathies, sparing the 
extraocular muscles and the heart (Clarke 2011a). 
 
2.2.2.2 Clinical picture of congenital fibre-type disproportion 
To make a diagnosis of CFTD, a disproportionate fibre size must present as the main 
diagnostic abnormality; furthermore, the diagnosis is only appropriate when other forms of 
congenital myopathy are excluded. Modest degrees of FSD may also occur in a wide range of 
other neuromuscular disorders, which must be considered and ruled out before diagnosing 
CFTD (Clarke 2011b, Clarke 2011a). Patients with CFTD may present with many of the 
clinical features of congenital myopathies: static or slowly progressing generalised weakness, 
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prominent axial or respiratory weakness, facial weakness, dysphagia and, in rare cases, 
ophthalmoplegia. No single clinical or histologic feature is specific to CFTD (Clarke 2011a). 
 
2.2.2.3 Muscle pathology of congenital fibre-type disproportion 
The main histologic feature that defines CFTD is an abnormality in the muscle fibre size 
(Figure 4). Initially, a difference in fibre size of more than 12% was considered characteristic 
of CFTD (Brooke 1973). Recently, findings suggest that, in CFTD, type-1 (slow twitch) 
muscle fibres are smaller compared with type-2 (fast twitch) muscle fibres by at least 35–40% 
(Clarke 2011a). 
 
2 Aims of the study 
This study aims to increase our understanding of the pathogenetic mechanisms of congenital 
myopathies caused by mutations in the tropomyosin and nebulin genes and to compile as 
many as possible of the known and novel mutations in the TPM2 and TPM3 genes causing 
congenital myopathies to determine any genotype–phenotype correlations.  
 
 
3 Materials and methods 
 
3.1 Polymerase Chain Reaction (PCR) and sequencing 
Genomic DNA was extracted from whole blood or other tissues using standard protocols. The 
protein coding regions and the intron–exon borders of TPM2 and TPM3 were amplified using 
standard procedures and the bi-directional sequence was determined using Sanger di-deoxy 
methods. 
 
3.2 Constructs 
TPM2 cDNA (GenBank® accession number NM_009416) cloned into pGEX4-1 (GE 
Healthcare) was used as a template for PCR. Forward 5_-
GATCCATGGACGCCATCAAGAAGAAG-3_ and reverse 5_-
TCGAGTCAGAGGGAAGTGATGTCAT-TG-3_ primers were designed to copy the TPM2 
sequence and to exclude the GST tag. Fusion DNA polymerase (Thermo Fisher Scientific) 
was used. Products were cloned into the Zero Blunt TOPO vector using a PCR cloning kit 
(Invitrogen). Plasmids were extracted using QIAprep Spin Miniprep kit (Qiagen). The 
mutations (Table 1) were introduced into mouse cDNA using the QuikChange® Site-Directed 
Mutagenesis kit (Stratagene). Plasmids were sequenced using BigDye version 3.1 sequencing 
chemistry and an ABI 3730 DNA Analyzer (Applied Biosystems). The sequences were 
analysed using the Sequencher 4.5 software. 
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Table 1. Mutations in TPM2 gene. 
Mutation Location Disease Reference 
E117K Exon3 NM Donner et al. 2002 
Q147P Exon4 NM Donner et al. 2002 
E139del Exon4 Cap myopathy Lehtokari et al. 2007 
K49del Exon 2 Cap myopathy Ohlsson et al. 2007 
E41K Exon 2 Cap myopathy Ohlsson et al. 2007 
 
 
 
3.3 Production of wild-type and aberrant β-tropomyosins 
Recombinant β-Tms were produced using a Bac-to-Bac baculovirus expression system 
(Invitrogen; http://tools.lifetechnologies.com/content/sfs/manuals/bactobac_man.pdf) in 
Spodoptera frugiperda (Sf9) insect cells. The insect cells were grown in a supplemented 
Grace’s Insect Medium (Invitrogen) containing 10% fetal bovine serum (Gibco) and 1% 
penicillin/streptomycin (Gibco) in 500 ml of medium at 27
◦
C (Figure 6). 
 
 
 
Figure 6. β-tropomyosins produced in insect cells. SDS-PAGE of recombinant proteins stained with 
Coomassie Blue. The β-tropomyosin mutations p.K49del and p.E139del result in altered protein 
conformation and, thus, slower migration in the SDS-PAGE gel. Modified from Biochem J. 2012 
15;442(1):231–9 with permission from the Biochemical Society. 
 
3.3.1 Extraction of proteins 
Proteins were extracted from Sf9 cells using a modification of the method described by 
Akkari et al. (Akkari et al. 2002), which is described in detail elsewhere (Marttila et al. 2012).  
 
3.4 RNA isolation and reverse transcriptase polymerase chain reaction (RT-PCR) 
Total RNA was isolated from human vastus lateralis (VL) muscles using the RNeasy Fibrous 
Tissue Mini Kit (Qiagen). cDNA was synthesised from 2 µg of total RNA using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Next, 2 µl of template were 
used per 20-µl PCR reaction. All PCR reagents were from Thermo Scientific. Amplifications 
were completed using Phusion High-Fidelity DNA polymerase and PCR products were 
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cloned into pCRBluntII-TOPO (Invitrogen). For all nebulin exon amplifications, after initial 
heating at 98
o
C for 1 min, 30 cycles of denaturation at 98
o
C for 10 s, annealing at 59
o
C for 30 
s and extension at 72
o
C for 15 s were performed, followed by a final extension of 10 min at 
72
o
C.  
 
3.5 In vitro mutagenesis and sequencing 
The QuickChange site-directed mutagenesis kit (Stratagene) was used to introduce site-
specific point mutations or deletions into NEB cDNA fragments (Table 3). PCR reactions 
were performed using DNA as a template with two synthetic oligonucleotide primers 
containing the chosen mutation (Table 2). The cycling conditions were completed as 
recommended in the manual and the primer details are given in Table 2. The purified products 
were sequenced using BigDye version 3.1
 
sequencing chemistry and an ABI 3730 DNA 
Analyser (Applied Biosystems,
 
Foster City, USA). Sequences were analysed using the 
Sequencher
 
4.1 software. The primers used for nebulin exon amplifications and in vitro 
mutagenesis are summarised below (Table 3).  
 
 
Table 2. NM-causing NEB mutations. The site of the mutations is reported according to the coding 
sequence of NEB cDNA GenBank ID NM_001164507.1 and its translation, NP_001157979.1. 
Fragment Mutations in 
cDNA 
Altered protein 
site  
Disease Reference 
Neb ex53-57  
(super-repeat 9) 
in figures ex54m 
c.7291G>A p.Glu2431Lys NM mild form Lehtokari et 
al. 2006 
Neb ex53-57  
(super-repeat 9) 
in figures 
ex55del 
c.7432+1916_7535
+372del 
p.Arg2478_Asp251
2del 
NM 
severe, 
intermediate and 
typical forms 
Lehtokari et 
al. 2006 
Neb ex 77-81 
(super-repeat 14) 
in figures 
ex78del 
 c.11770_11787del p.Val3924_Asn392
9del 
NM mild form Lehtokari et 
al. 2006 
Neb ex 119-125 
(super-repeat 18) 
in figures 
ex122m 
c.19097G>T p.Ser6366Ile NM typical 
form, distal 
myopathy 
Lehtokari et 
al. 2006 
Neb ex 146-153 
(super-repeat 22) 
in figures 151m 
c.22144A>C p.Thr7382Pro NM typical 
form, distal 
myopathy 
Lehtokari et 
al. 2006, 
Wallgren-
Pettersson et 
al. 2007 
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Table 3. Oligonucleotide primers used for cloning nebulin super-repeats and for in vitro 
mutagenesis. 
 Primer name 5’-3’ Sequence Experimental use 
1 Ex 54-F CGC GAA TTC CAA GGC TAC CGA AAG CAA cDNA amplification 
2 Ex 54-R CCG CTC GAG ATC GCT CTG GAG GTC ATA 
GGC 
cDNA amplification 
3 Ex 78-F2 TAC GGA TCC AAG TAC AAG GAA GGC TAC 
CG 
cDNA amplification 
4 Ex 78-R1 TTT CTC GAG TGC TTG GAT AAT GTC GTT 
TTG 
cDNA amplification 
5 Ex 122-F1 GCG GGA TCC GAG AAG CAG AAA GGT CAC 
TAC 
cDNA amplification 
6 Ex 122-R CCG CTC GAG GAT GTT AAG CTT GCC AAC 
TCG 
cDNA amplification 
7 Ex 151-F CGC GAA TTC AAA TTG GAA TAC AAC AAG 
GCC 
cDNA amplification 
8 Ex 151-R CCG CTC GAG TTT GGC TGC CTG TGT GGC cDNA amplification 
9 Ex 54MUT-
F 
gatggagtcccttgggttctttaaaggcagaaaagaac In vitro mutagenesis 
10 Ex 54MUT-
R 
gttcttttctgcctttaaagaacccaagggactccatc In vitro mutagenesis 
11 Ex 78del-F cattaccgacactccggaaattgccctgacaatgAGCAAG In vitro mutagenesis 
12 Ex 78del-R CTTGCTcattgtcagggcaatttccggagtgtcggtaatg In vitro mutagenesis 
13 Ex 
122MUT-F 
actgctgttcagagtggcattaatgccattgaggtaaaatataa In vitro mutagenesis 
14 Ex 122MUT 
R 
ttatattttacctcaatggcattaatgccactctgaacagcagt In vitro mutagenesis 
15 Ex 
151MUT-F 
ttcacgtcaaggaagtgcccaagcatgtcagtgat In vitro mutagenesis 
16 Ex 151MUT 
R 
atcactgacatgcttgggcacttccttgacgtgaa In vitro mutagenesis 
17 Ex 78del-F cattaccgacactccggaaattgccctgacaatgAGCAAG In vitro mutagenesis 
18 Ex 78del-R CTTGCTcattgtcagggcaatttccggagtgtcggtaatg In vitro mutagenesis 
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3.6 Construction of vectors for the expression of nebulin super-repeats 
Plasmid vectors for the expression of human NEB super repeats 14 and 18 for the analysis of 
exon 78 and exon 122 were constructed by cloning digested and purified PCR products into 
the BamHI/XhoI restriction sites of the pGEX4T-1 expression vector. Plasmid vectors for the 
expression of super-repeats 9 and 22 for the study of exon 54 and exon 151 were constructed 
by cloning digested and purified PCR products into the EcoRI/XhoI restriction sites of the 
pGEX4T-1 expression vector.  
 
3.7 Nebulin production in Escherichia coli 
GST-NEB fusion proteins were expressed from the pGEX-4T vectors in Escherichia coli (E. 
coli) strain BL21 (DE3) (Invitrogen). Proteins were expressed by selecting a single colony 
and culturing in 5-mL LB supplemented with ampicillin (100 µg/ml). After growing the E. 
coli sample to A600 0.5–0.8, the cells were induced with 0.5-mM isopropyl-β-D-
thiogalactopyranoside (IPTG) for 3 h at 250 rpm at 27.8°C. Harvesting of cells and batch-
binding protein purifications were performed as described in the manufacturer’s manual 
(Protino® Glutathione Agarose 4B, Macherey-Nagel, MN, Germany) (Figure 7). 
 
 
 
Figure 7. Purified GST (glutathione-S-transferase)-nebulin and tropomyosin. GST-nebulin domains 
were produced in Escherichia coli strain BL21, while α-tropomyosins (Tm3) and β-tropomyosins 
(Tm2) were produced in insect cells. The proteins were purified, run in a SDS-PAGE gel and stained 
with Coomassie Blue. Modified from Marttila et al. 2014 Skeletal Muscle 1;4:15. 
 
 
3.7.1 Actin binding 
Actin-binding assays were performed using Cytoskeleton’s Actin-Binding Protein Biochem 
Kit (Cytoskeleton). Here, 10.35-μM β-tropomyosins and 23-μM F-actin were used to detect 
more actin-binding mutants. Tms were allowed to bind to F-actin for 30 min at room 
temperature. Samples were run in a Beckman Coulter OptimaMAXUltracentrifuge at 60 000 
rpm for 1.5 h at 24
◦
C. Pellet and supernatant fractions were separated, analysed using 12% 
SDS-PAGE gels and stained with Coomassie Blue. Pellet and supernatant bands were 
quantified from four duplicated experiments using the ImageJ program (NIH). The 
significance was calculated using a one-tailed distribution and unpaired Student's t test. 
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3.7.2 GST-pulldown assays 
GST-containing wt and mutant NEB super-repeats (8 µg) bound to beads were mixed with 
baculovirally produced and purified wt α-tropomyosin, wt β-tropomyosin and mutant β-
tropomyosins (40 µg) in 400-µl PBS in a shaker at +4°C for 45 min. Samples were 
centrifuged at 2000 rpm for 5 min. The supernatant was removed and 400-µl fresh 1xPBS was 
added. Samples were washed 5 times by centrifugation at 1500-2000 rpm for 5 min. The 
pellets were dissolved in a 20-µl Laemmli sample buffer, analysed in 12% SDS-PAGE gels 
and stained with Coomassie Blue. Bands of pelleted protein were quantitated from three 
duplicated experiments using the ImageJ program. 
 
3.8 Three-dimensional models 
The mutations E41K, K49del and E139del were created in the amino acid sequence of Tm2 
(GenBank® accession number P58775.1). The probable secondary structure of the mutants 
were assigned through homology modelling using the crystal structure corresponding to PDB 
codes 1C1GA and 2B9CA as templates following a standard method in Discovery Studio 
(Accelrys). 
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4 RESULTS AND DISCUSSION 
 
4.1 Novel mutations in TPM2 and TPM3 
Mutations in the tropomyosin genes have been generally uncommon. Altogether 14 mutations 
in TPM2 and 16 in TPM3 were known to be associated with congenital myopathies (Citirak et 
al. 2014) before our study. NM, cap myopathy, core-rod myopathy, CFTD, DA and Escobar 
syndrome are caused by mutations affecting skeletal muscle isoforms of the tropomyosin 
genes. Including previously published research, 94 families were included in our study of 
tropomyosin mutations (Marttila et al. 2014a). Of these, 53 had TPM2 mutations and 41 had 
TPM3 mutations. There were 30 different mutations in TPM2 and 20 different mutations in 
TPM3. Eleven of the TPM2 mutations and 5 of the TPM3 mutations were novel (Figures 8 
and 9, Tables 4 and 5). No clinical details were available for 12 TPM2 families and 5 TPM3 
families. None of the novel changes were found in the 1000 Genomes dataset 
(www.1000genomes.org) nor in the Exome Variant Server, NHLBI Exome Sequencing 
Project (ESP), Seattle, WA (http.//evs.gs.washington.edu/EVA/).  
 
 
 
Figures 8 and 9. The Tm2 and Tm3 dimers presented in green with disease-causing mutations (shown 
in red and above the molecules), α-zones (purple) and overlapping regions (separated by green lines in 
N- and C-terminal ends of the molecules). Phosphorylation sites are shown below the molecules. 
Novel mutations/phosphorylation sites are shown in yellow. The figure was created using the PyMol 
software (http://www.pymol.org) and the Protein Databank structure 1C1GA. Modified from Marttila 
et al. Hum Mutat. 2014 35(7):779-90 with permission from Wiley. 
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Molecular testing for congenital myopathies is evolving rapidly with advances in next 
generation sequencing technologies. This will have an impact on the method of genetic testing 
for these diseases. A novel custom comparative genomic hybridization microarray, NM-CGH, 
was developed including the seven known genes causative for NM. Two novel deletions 
mutations were identified using this method in two different families (Kiiski et al. 2013). The 
whole-exome sequencing of six families and targeted gene sequencing of additional families 
identified 19 mutations in the KLHL40 (Ravenscroft et al. 2013b). The whole-exome 
sequencing identified recessive small deletions and missense changes in the KLHL41 in four 
individuals from unrelated NM families (Gupta et al. 2013). Exome sequencing revealed 88 
heterozygous carriers of pathogenic nebulin mutations and disease incidence of approximately 
1 in 18300 for recessively inherited myopathies caused by nebulin mutations (Lehtokari et al. 
2007). The challenge will be to ensure that sequence changes identified are pathogenic and to 
distinguish these from polymorphisms. This may be done by using prediction programs or 
database searches. The Leiden Open Variation database (LOVD) is an open access database 
that provides a list of DNA sequence variants in specific genes and associated phenotypes to 
assist in the identification of pathogenic variants (http://www.lovd.nl/) (North et al. 2014). 
The novel TPM2 and TPM3 variants found in our study have been inserted in the LOVD 
database. Collecting all the data is essential for the researchers working in the field of rare 
diseases as well as for the diagnostic laboratories screening for mutations in these genes. 
 
 
Figure 10. Sequence comparison of α-tropomyosin, β-tropomyosin and γ-tropomyosin (TPM1, TPM2 
and TPM3). Mutations are indicated in the sequence by red dots. In the Tm3 protein amino-acid 
sequence (P06753) the initiation codons have been processed, thus the nomenclature is different 
compared with that in other figures. The tropomyosin head-to-tail overlapping regions are marked as 
black boxes at the end of the molecules. Stars below the sequences indicate conserved amino acids, 
and dots show the sites where sequences diverge. Modified from Marttila et al. Hum Mutat. 2014 
35(7):779-90 with permission from Wiley. 
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4.1.1 Prediction of pathogenicity of mutations 
The prediction programs of functional effects of human non synonymous single nucleotide 
polymorphisms (SNPs) PolyPhen-2, and FATHMM were used to predict the pathogenicity of 
missense mutations in TPM2 and TPM3.  Our analysis shows that both PolyPhen-2 and 
FATHMM were able to correctly predict more than 80% of the pathogenic Tm mutations 
(82.5% for PolyPhen-2 and 85% for FATHMM). Out of 22 TPM2 mutations 17 were 
predicted to be possibly or probably damaging (Table 4). The two programmes gave slightly 
different results in the predictions. PolyPhen-2 predicted three mutations (p.Asp2Val, 
p.Ala3Gly, p.Arg91Gly) to be benign, whereas FATHMM predicted the same three mutations 
to be damaging. FATHMM predicted the mutation p.Gln147Pro to be tolerated, whereas 
PolyPhen-2 predicted the same mutation to be probably damaging. Both programs predicted 
two mutations (p.Glu41Lys and p.Asn202Lys) to be benign or tolerated, but the functional 
studies have shown that p.Glu41Lys affects muscle contractility due to decreased calcium 
sensitivity (Marttila et al. 2012) and transfected human myotubes with the p.Glu41Lys mutant 
showed perinuclear aggregates (Abdul-Hussein et al. 2013). A range of contractile 
characteristics in skinned muscle fibres were investigated in patients with p.Glu41Lys 
mutation and healthy controls. Results showed decreases in speed of contraction at saturated 
Ca
2+
 concentration and in contraction sensitivity to Ca
2+
 concentration suggesting that the 
mutation has a negative effect on contractile function, contributing to the muscle weakness 
(Ochala et al. 2008). Using X-ray diffraction it was shown that p.Glu41Lys β-tropomyosin 
mutation does not change the myofilament lattice geometry and therefore may not have any 
detrimental influence on the contraction mechanisms or on the rate of force generation 
(Ochala, Iwamoto 2013a). The β-tropomyosin mutant p.Asn202Lys that has been 
hypothesized to affect Tm-Troponin T interactions, failed to integrate into thin filaments and 
formed accumulations in myotubes (Abdul-Hussein et al. 2013, Ohlsson et al. 2008). 
PolyPhen-2 predicted 16/18 missense mutations to be possibly or probably damaging in 
TPM3 and 17 were predicted to be damaging by FATHMM (Table 5).  
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Table 4. Novel and recurrent TPM2 mutations with functional significance. Nucleotide numbering 
according to the TPM2 cDNA sequence with +1 corresponding to the A of the ATG translation 
initiation codon in the reference sequence NM_003289.3. Amino acid coordinates are provided 
relative to NP_003280.2, the ATG translation initiation codon is codon 1. Abbreviations: NM, 
nemaline myopathy; Cap, cap myopathy; CFTD, congenital fibre type disproportion; DA, distal 
arthrogryposis; CRM, core-rod myopathy; CM, undefined congenital myopathy; spl, splice site 
mutation; # gain-of-function mutation resulting in hypercontractile phenotypes.  
TPM2 mutations with functional significance 
Family 
 
Patient 
ID, 
Gender 
Mutation(s) 
in cDNA 
RefSeq 
NM_003289.
3 
Altered 
protein site 
and 
predicted 
effect 
Diagnosis Functional significance 
Fam 1 
 
- c.5A>T p.Asp2Val - head-to-tail binding 
Fam 2 
 
2693 
M 
c.8C>G p.Ala3Gly NM head-to-tail binding 
Fam 3 
 
20-625 
F 
c.41A>T p.Asp14Val NM adjacent to On state 
tropomyosin-actin contacts 
Fam 4 
 
20-561 
F 
c.124G>A p.Glu41Lys NM decreased Ca
2+
 sensitivity 
Fam 5 
 
M c.144_146 
delGAA 
p.Lys49del Cap decreased actin affinity, 
decreased α-helical content in 
circular dicroism 
Fam 6# 
 
F c.240+5G>A spl DA increased contractility 
Fam 7 
 
F c.349G>A p.Glu117Lys DA decreased Ca
2+
 sensitivity, 
increased actin affinity, 
increased α-helical content in 
circular dicroism 
Fam 8# 
 
20-393 
M 
c.382A>G p.Lys128Glu CM increased contractility 
Fam 9#  
 
3603 
F 
c.397C> T p.Arg133Trp CFTD increased contractility 
 F c.440A>C p.Gln147Pro NM 
Cap 
decreased actin affinity 
Fam 
10# 
3653 
F 
c.443T>C p.Leu148Pro CFTD increased contractility 
Fam 11 
 
F c.541G>A p.Glu181Lys NM increased Ca
2+
 sensitivity and 
force production 
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Fam 12 
 
- c.654_656del p.Glu218del - adjacent to On state 
tropomyosin-actin contacts 
Recurrent mutations with functional significance 
Fam 13# 
 
Fam A 
F  
c.19_21delAAG p.Lys7del NM head-to-tail binding, increased 
contractility 
Fam 
14# 
 
Fam B 
M  
c.19_21delAA
G 
p.Lys7del NM head-to-tail binding, increased 
contractility 
Fam 
15# 
 
Fam C 
F  
c.19_21delAA
G 
p.Lys7del NM head-to-tail binding, increased 
contractility 
Fam 
16# 
 
Fam D 
M  
c.19_21delAA
G 
p.Lys7del NM head-to-tail binding, increased 
contractility 
Fam 17 
 
Fam E 
1653    F  
c.19_21delAA
G 
p.Lys7del NM head-to-tail binding, increased 
contractility 
Fam 
18# 
 
20-747 
F 
c.19_21delAA
G 
p.Lys7del NM head-to-tail binding, increased 
contractility 
Fam 
19# 
Fam 1 
M 
c.19_21delAA
G 
p.Lys7del CRM head-to-tail binding, increased 
contractility 
Fam 
20# 
Fam 2 
F 
c.19_21delAA
G 
p.Lys7del  DA type 7 head-to-tail binding, increased 
contractility 
Fam 
21# 
Fam 3 
F 
c.19_21delAA
G 
p.Lys7del  DA type 7 head-to-tail binding, increased 
contractility 
Fam 
22# 
Fam 4 
F 
c.19_21delAA
G 
p.Lys7del  DA type 7 head-to-tail binding, increased 
contractility 
Fam 23 
 
291-A, B 
F, M 
c.415_417del
GAG 
p.Glu139del NM 
Cap  
decreased actin affinity, decreased 
α-helical content in circular 
dicroism, adjacent to On state 
tropomyosin-actin contacts 
Fam 24 F c.415_417del
GAG 
p.Glu139del CFTD decreased actin affinity, decreased 
α-helical content in circular 
dicroism, adjacent to On state 
tropomyosin-actin contacts 
Fam 25 
 
3073 
M 
c.415_417del
GAG 
p.Glu139del Cap 
CFTD 
decreased actin affinity, decreased 
α-helical content in circular 
dicroism, adjacent to On state 
tropomyosin-actin contacts 
Fam 26 
 
F c.415_417del
GAG 
p.Glu139del Cap  
 
decreased actin affinity, decreased 
α-helical content in circular 
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dicroism, adjacent to On state 
tropomyosin-actin contacts 
Fam 27 
 
F c.415_417del
GAG 
p.Glu139del Cap 
CFTD 
decreased actin affinity, decreased 
α-helical content in circular 
dicroism, adjacent to On state 
tropomyosin-actin contacts 
 
 
 
 
Table 5.  Novel and recurrent TPM3 mutations with functional significance. Nucleotide numbering 
according to the coding sequence of the TPM3 cDNA reference sequence NM_152263.3. The first 2 
ATG codons in the primary cDNA were both included according to the Human Genome Variation 
Society recommendations. Amino acid coordinates are provided relative to NP_689476.2, the ATG 
translation initiation codon is codon 1. Abbreviations: NM, nemaline myopathy; Cap, cap myopathy; 
CFTD, congenital fibre type disproportion; CM, undefined congenital myopathy; spl, splice site 
mutation; # gain-of-function mutation resulting in hypercontractile phenotypes.  
TPM3 mutations with functional significance 
Family 
 
Patient 
ID, 
Gender 
Mutation(s) 
incDNA 
RefSeq 
NM_152263.3 
Altered protein 
site and 
predicted effect 
Diagnosis 
 
Functional significance 
Fam 1 
 
F, M c.11C>T (p.Ala3Val) 
p.Ala4Val 
CFTD head-to-tail binding 
Fam 2 
 
F, M c.26T>G (p.Met8Arg) 
p.Met9Arg 
NM head-to-tail binding 
Fam 3 
 
F c.298C>G (p.Leu99Val) 
p.Leu100Val 
CFTD adjacent to On state 
tropomyosin-actin contacts 
Fam 4 F c.298C>A (p.Leu99Met) 
p.Leu100Met 
CFTD adjacent to On state 
tropomyosin-actin contacts 
Fam 5 
 
M c.733A>G (p.Arg244Gly) 
p.Arg245Gly 
CFTD decreased Ca
2+
 sensitivity 
Fam 6 F c.915A>C 
 int 9 splice 
mutation 
(p.Stop284Ser) 
p.Stop285Ser 
NM head-to-tail binding 
Fam 7 F c.857A>C (p.Stop284Ser) 
p.Stop285Ser 
CFTD head-to-tail binding 
Fam 8 F, M c.913delA (p.Stop284Asn
) 
p.Stop285Asn 
extStop74 
NM head-to-tail binding 
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Recurrent mutations with functional significance 
Fam 9 
 
F c.503G>A (p.Arg167His) 
p.Arg168His 
CFTD decreased Ca
2+
 sensitivity, 
decreased myosin cross-bridges 
bound to actin 
Fam 10 
 
M c.503G>A (p.Arg167His) 
p.Arg168His 
CFTD decreased Ca
2+
 sensitivity,  
decreased myosin cross-bridges 
bound to  
actin 
Fam 11  F, M 
  
c.503G>A (p.Arg167His) 
p.Arg168His 
NM 
CFTD 
decreased Ca
2+
 sensitivity,  
decreased myosin cross-bridges 
bound to 
actin 
Fam 12 M c.503G>A (p.Arg167His) 
p.Arg168His 
NM decreased Ca
2+
 sensitivity,  
decreased myosin cross-bridges 
bound to  
actin 
Fam 13 M c.503G>A (p.Arg167His) 
p.Arg168His 
Cap decreased Ca
2+
 sensitivity,  
decreased myosin cross-bridges 
bound to  
actin 
Fam 14 BOS 
247-4  
F 
c.503G>A 
 
(p.Arg167His) 
p.Arg168His 
CFTD decreased Ca
2+
 sensitivity,  
decreased myosin cross-bridges 
bound to 
actin 
Fam 15 BOS 
343-1 
M 
c.503G>A 
 
(p.Arg167His) 
p.Arg168His 
NM decreased Ca
2+
 sensitivity,  
decreased myosin cross-bridges 
bound to 
actin 
Fam 16 F 
 
c.503G>A 
 
(p.Arg167His) 
p.Arg168His 
(RYR 
p.Arg3539His) 
CFTD decreased Ca
2+
 sensitivity,  
decreased myosin cross-bridges 
bound to actin 
Fam 17 F c.503G>A 
 
(p.Arg167His) 
p.Arg168His 
CFTD decreased Ca
2+
 sensitivity,  
decreased myosin cross-bridges 
bound to 
actin 
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4.1.2 Recurrent mutations in TPM2 and TPM3 
Two recurrent mutations were found in TPM2. The first is p.Lys7del, which was found in 10 
families (Davidson et al. 2013, Mokbel et al. 2013, Marttila et al. 2014a). The second one is 
p.Glu139del, which has been reported in 5 families (Lehtokari et al. 2007, Clarke et al. 2009, 
Marttila et al. 2014a, Tasca et al. 2013). The amino acid Arg133 in TPM2 is a mutational 
hotspot. In three unrelated families it is mutated to tryptophan (p.Arg133Trp), and another 
two unrelated families share the mutation p.Arg133Pro (Tajsharghi et al. 2007a, Marttila et al. 
2014a). The p.Arg133Trp mutation caused distal arthrogryposis type 2B in two families, and 
NM with congenital arthrogryposis and CFTD in one family (Figures 10 and 11, Table 4) 
(Tajsharghi et al. 2007a, Marttila et al. 2014a). The p.Arg133Trp mutation has been shown to 
hinder both calcium- and myosin-induced tropomyosin movement over the thin filament, 
blocking actin conformational changes and consequently decreasing the number of cross-
bridges and subsequent force production (Ochala et al. 2010). The p.Arg133Pro mutation has 
been reported to cause CFTD (Marttila et al. 2014a). 
The p.Arg168 residue was mutated in 21 families and is the one mutational hotspot in TPM3. 
The recurrent mutation p.Arg168His was present in 12 families and caused NM, cap 
myopathy and CFTD (Clarke et al. 2008, Marttila et al. 2014a, Durling et al. 2002, De Paula 
et al. 2009, Lawlor et al. 2010, Penisson-Besnier et al. 2007). Eight families had the 
p.Arg168Cys mutation also resulting in NM, cap myopathy and CFTD phenotypes (Clarke et 
al. 2008, Marttila et al. 2014a). One family had p.Arg168Gly mutation causing CFTD (Clarke 
et al. 2008, Marttila et al. 2014a)(Table 5). In the fusion process in normal human muscle 
primary myotubes fuse to form myoblasts fusion determining the length of the muscle fibre 
and newly created myoblasts fuse with the existing myotubes to generate proper muscle 
fibres. The p.Arg168Gly mutation in the TPM3 gene delayed and changed the process of 
fusion, resulting in the feature of hypotrophic Type 1 fibres. The cap structures peripherally 
located in hypotrophic Type 1 fibres are at the beginning of myoblasts which were not able to 
align and fuse properly with primary myotubes. The lack of normal TPM3 protein has been 
suggested to result in modified sarcomere architecture in cap structures (Fidzianska, Madej-
Pilarczyk & Hausmanowa-Petrusewicz 2014). 
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Figure 11. Schematic presentation of β-tropomyosin (Tm2) dimer with disease-causing mutations 
(shown in red and above the molecules), α-zones (purple) and overlapping regions (separated by lines 
in N- and C-terminal ends of the molecules). Mutations in the TPM2 are marked in the structure. The 
green highlight residues interacting with actin Asp25 defined by Li et al (2010).  Mutation hotspot 
Arg133 and recurrent mutations p.Lys7del and p.Glu139del are indicated by black arrows below the 
sequence. The figure was created using the PyMol software (http://www.pymol.org) and the Protein 
Databank structure 1C1GA. 
 
4.2 Clinical correlations 
Congenital myopathy phenotypes can be classified into two types: those that are characterised 
by congenitally weak muscles and those with congenitally normal or hypercontractile muscles 
(e.g. DA). Contractility is the major factor altered by mutations in contractile proteins such as 
tropomyosin. A single mutation in an essential protein can cause a range of phenotypes 
making the classification of the disorders challenging. This was presented in two articles 
describing the Lys7del mutation in TPM2 (Davidson et al. 2013, Mokbel et al. 2013). The 
recognition of any clinical and histological genotype-phenotype correlation is difficult since 
there is great variability in phenotypes within the 10 families described. Wide phenotypic 
heterogeneity was also noted in patients with TPM2 (p.Glu139del) and TPM3 mutations 
(p.Arg168His and p.Arg168Cys) (Citirak et al. 2014). NM, cap myopathy and CFTD are 
related disease entities with largely overlapping clinical features. DA and Escobar syndrome 
may be seen as more distinct clinical entities with less overlap with other disorders in the 
group. Distal contractures may seen in all the disease groups. The disorders are usually 
relatively stable entities that do not overlap much with other diagnoses. CFTD does not fulfill 
either of the previous: its main diagnostic feature is present in most other congenital 
myopathies and the disease often evolves into another one with time. There has been 
discussion whether CFTD should be regarded as a separate disease entity, but many find it as 
a useful diagnostic category. The main reason is that it fulfills a clinical need. It provides a 
diagnosis for a group of patients who do not fall into any other diagnostic category. The 
concept of CFTD was created soon after the development of the first histolochemical staining 
methods to analyse the variation in myofibre sizes and proportions that can be associated with 
neuromuscular disorders. It was a time of rapid advancement in the classification of 
myopathies (Clarke 2011a).  
        There was no difference in the age at presentation of the disease between patients with 
mutations in the TPM2 and TPM3. In both, the majority presented perinatally or in infancy, a 
smaller number in childhood, with delayed motor milestones, and few in adulthood. Nine out 
 42 
 
of 53 patients with TPM2 mutations presented with distal arthrogryposis, while this was not 
present in patients with TPM3 mutations. Patients with recurrent deletion mutation Lys7del 
along the 5’ end of the gene presented with camptodactyly (2/10), core-rod myopathy (1/10), 
contractures (4/10) and difficulty opening their mouth (4/10) (Davidson et al. 2013, Mokbel et 
al. 2013). Nemaline bodies were also present in patients with a diagnosis of DA type 7 (3/3) 
showing the overlap between phenotypic characteristics of these disease entities. The 
congenital myopathies are due to mutations in more than one gene and the histological 
features on muscle biopsies can occur on a spectrum that crosses the boundaries of individual 
genetic entities (Nance et al. 2012, North et al. 2014).  
        In most families the disease-causing mutations were heterozygous, and the mode of 
inheritance dominant (89 families). Of the heterozygous mutations, 43 had occured de novo. 
Few TPM3 mutations were homozygous and these were all found in the beginning or at the 
end of the gene. Most recessive mutations were nonsense mutations changing an amino acid 
to a stop codon, yielding a truncated protein or changing the stop codon to give rise to a 
longer protein. The dominant mutations were mostly missense mutations or in-frame 
deletions.  Among patients with TPM2 mutations, only one was homozygous for a recessive 
mutation. There was one case of mosaicism associated with a heterozygous TPM2 mutation. 
In the TPM3 group, four families showed the recessive mode of inheritance, and there was 
one case of probable mosaicism. Family with autosomal dominant inheritance with cap 
myopathy in three generations, caused by a novel heterozygous p.Leu149Ile mutation in exon 
4 of TPM3 have been recently reported (Schreckenbach et al. 2014). This is described to be 
the first dominant case of cap myopathy in TPM3. However, we report in our study 5 
dominant cases of cap myopathy in TPM3. Most of the cases are due to de novo mutations.   
        Patients included in the present study with various disease entities commonly had type 1 
fibre predominance and hypotrophy except for the case of Escobar syndrome. Fibre size 
disproportion appeared to be consistent among all patients with TPM3 mutations and type 1 
hypotrophy is to be expected in patients with TPM3 mutations because of the exclusive 
expression of Tm3 in type 1 fibres (Perry 2001). However, small type 1 fibres were common 
also in the group with TPM2 mutations. Caps were more commonly observed in patients with 
TPM2 mutations than in patients with TPM3 mutations (10/41 versus 5/35). The variable 
observations of caps and/or nemaline bodies in families and even in individual patients over 
time (Lehtokari et al. 2007, Tajsharghi et al. 2007b) indicates that cap myopathy is a 
subcategory of NM. It has also been stated in previous studies that these two disorders are 
phenotypic variants of the same genetic defect (North et al. 2014, Tajsharghi et al. 2007b, 
Ohlsson et al. 2006). 
        Patients with hypercontractile molecular phenotypes more often have contractures of the 
limb joints (18/19) and jaw (6/19) than those who do not have this type of mutation (2/22 and 
1/22). Patients with non-hypercontractile molecular phenotypes much more often (19/22) 
have axial contractures (scoliosis and rigid spine) than the hypercontractile group (7/19). One 
hypercontractile molecular phenotype was found in TPM3 (p.Lys169Glu). Three TPM3 
mutations at the hypercontractile sites are known altogether (unpublished data). 
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4.3 Genotype-phenotype correlations 
 
4.3.1 Actin affinity for wild type and mutant β-tropomyosins 
NM is most commonly a disorder of thin filament proteins. To understand the pathogenetic 
mechanisms underlying NM it is necessary to understand the normal interactions of these 
proteins. Mutations in the genes encoding various components of the thin filament likely 
disrupt the orderly assembly of sarcomeric proteins and the functional interaction between the 
thin and thick filaments during muscle contraction The wt and β-tropomyosins with human 
disease-causing mutations showed differences when tested for actin binding: p.Lys49del, 
p.Glu139del and p.Gln147Pro showed significantly weaker affinity for actin than wt and 
p.Glu117Lys bound actin more strongly. The aberrant β-tropomyosin harbouring mutation 
p.Glu41Lys did not show any significant change in actin binding (Figure 11).  
 
 
 
Figure 11. F-actin co-sedimentation assay (A) with wt β-tropomyosin and β-tropomyosin 
mutants. The supernatants (S) and pellets (P) were separated, run on SDS/PAGE and 
Coomassie Blue stained. Molecular masses (in kDa) are given in the centre of each panel. (B) 
Quantification of actin–Tm co-sedimentation assay. Gels were quantified to determine the 
mean relative intensities of four independent actin co-sedimentation assays (P/Pwt:S/Swt). 
Results are means±S.D. of each sample. P values (WT compared with mutant) for the samples 
are 0.0007, 0.0392, 0.0001, 0.0029, 0.0013 and 0.2417, respectively, using one-tailed 
distribution and the unpaired Student's t test. *Significant difference from the wt. 
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The p.Lys7del β-tropomyosin bound filamentous actin with low affinity in vitro. The wt 
isoforms of β-tropomyosin, α-tropomyosinslow and α-tropomyosinfast, are also available for 
dimer formation for mutant p.Lys7del in patient muscle and this enables it to incorporate into 
the sarcomere (Mokbel et al. 2013). This is also probably the case with p.Lys49del, 
p.Glu139del and p.Gln147Pro mutants with highly reduced affinity for filamentous actin in 
vitro. Mutations in patients with chronic generalized muscle weakness have generally resulted 
in reduced affinity of the mutant β-tropomyosin for actin, reduced myofilament Ca2+ 
sensitivity or impaired cross-bridge cycling  (Ochala et al. 2008, Mokbel et al. 2013). 
 
4.3.2 Tropomyosin-actin contacts 
Since many of the tropomyosin mutants altered actin affinity in our previous study (Marttila 
et al. 2012), we wanted to correlate the actin-tropomyosin interphase of newly discovered 
actin residues with those proteins altered by known the disease mutations. Tropomyosin 
forms contacts with actin through positively charged basic residues in the N-terminal part of 
an α-zone and acidic residues on the C-terminal side of an α-zone in the relaxed Off state. 
Tropomyosin interaction sites with actin in the Off state were precisely mapped by Li and co-
workers using electron microscopy and fibre diffraction studies of reconstituted F-actin-
tropomyosin filaments (Li et al. 2011). All 7 tropomyosin actin-binding repeats are predicted 
to interact with actin p.Asp25. A TPM2 mutation, p.Lys128Glu, and TPM3 mutations 
p.Arg91Pro/Cys, the hot-spot p.Arg168Cys/Gly/His and p.Arg245Gly/Ile all reside at one of 
these tropomyosin interaction sites. Gain-of-function mutations that increase contractility are 
located in the amino acid next to the Tm actin binding site: p.Lys7del, p.Lys49del and 
p.Arg91Gly in TPM2 and p.Lys169Glu in TPM3 (Memo, Marston 2013). Two acidic amino 
acids in each actin-binding repeat of tropomyosin, separated by 2-3 amino acids at the end of 
an α-zone, interact with actin amino acids 147, 326 and 328. Disease-causing mutations are 
found affecting only the first acidic amino acid and both are gain-of-function mutations: 
TPM2 p.Glu139del and p.Glu181Lys (Li et al. 2011, Memo, Marston 2013). Tropomyosin-
actin interaction sites in the Off state were also studied using mutagenesis (Barua, Pamula & 
Hitchcock-DeGregori 2011, Barua et al. 2012). The recently reported p.Leu149Ile mutation in 
TPM3 causing cap myopathy is next to the site of predicted actin contacts (Schreckenbach et 
al. 2014, Barua et al. 2012). The mutations in TPM2 and TPM3 resulting in congenital 
myopathies and their correlating actin contacts are summarised in tables 6 and 7 (unpublished 
data). It has been suggested that tropomyosin-actin binding, myosin cross-bridge formation 
and force production are the main pathogenetic mechanisms in tropomyosin-caused 
congenital myopathies (Ochala et al. 2012b). This is supported by our results since most 
mutations are found in regions important for tropomyosin-actin interaction. 
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Table 6. The mutations in TPM2 resulting in congenital myopathies and their correlating actin 
contacts. 
TPM2 mutation Reference Corresponding 
actin/(TnT) binding 
residue 
Reference 
K7del Mokbel et al. 2012 K6 Barua et al. 2011 
D14V Marttila et al. 2014a K15N Behrmann et al. 
2012 
K49del Ohlsson et al. 2008 K48 Barua et al. 2011 
S61P Clarke et al. 2012 E62 Barua et al. 2011 
R91G Sung et al. 2003 R90 Barua et al. 2011 
E117del Donner et al. 2002 
Brandis et al. 2008 
K118 Barua et al. 2012 
E122K Tajsharghi et al. 
2012 
D121, E122 Barua et al. 2012 
K128E Marttila et al. 2014a K128 Barua et al. 2011 
Li et al. 2011 
R133W Tajsharghi et al. 
2007 
S132 Li et al. 2011 
R133P Marttila et al. 2014a S132 Li et al. 2011 
E139del Lehtokari et al. 2007 
Marttila et al. 2012 
E139 Barua et al. 2011 
Li et al. 2011 
L148P Marttila et al. 2014a E150 Barua et al. 2012 
A155T Marttila et al. 2014a E156 Barua et al. 2012 
A155V Clarke et al. 2012 E156 Barua et al. 2012 
E181K Jarraya et al. 2012 E181 Li et al. 2011 
N202K Ohlsson et al. 2008 N202 Barua et al. 2011 
Q210X Monnier et al. 2009 K213 Barua et al. 2011 
E218del Marttila et al. 2014a D219 Barua et al. 2011 
Y261C Marttila et al. 2014a A262 TnT Murakami et al. 
2008 
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Table 7. The mutations in TPM3 resulting in congenital myopathies and their correlating actin 
contacts. 
TPM3 mutation Reference Corresponding 
actin/(TnT) binging 
site 
Reference 
M8R Laing et al. 1995 F86 TnT Murakami et al. 2008 
R90P Lawlor et al. 2010 R90 Barua et al. 2011 
R90C Marttila et al. 2014a R90 Barua et al. 2011 
L99M (L100M) Clarke et al. 2008 E97 Barua et al. 2011 
L99V Marttila et al. 2014a E97 Barua et al. 2011 
A155T  Kiphuth et al. 2010 E156 Barua et al. 2012 
R167C (R168C) Clarke et al. 2008 R167 Barua et al. 2011 
R167G (R168G) Clarke et al. 2008 R167 Barua et al. 2011 
R167H (R168H) Clarke et al. 2008 
Durling et al. 2002 
Penisson-Besnier et 
al. 2007 
De Paula et al. 2009 
Lawlor et al. 2010 
Marttila et al. 2014a 
R167 Barua et al. 2011 
R168E (R169E) Clarke et al. 2008 R167 Barua et al. 2011 
E240K (E241K) Lawlor et al. 2010 E240 Barua et al. 2011 
R244G (R245G) Clarke et al. 2008 R244 Barua et al. 2011 
R244I   (R245I)  Marttila et al. 2014a R244 Barua et al. 2011 
T253K Marttila et al. 2014a D254 Barua et al. 2011 
 
 
Tropomyosin moves relative to the actin filament and myosin contacts are formed in the ‘On’ 
state (Behrmann et al. 2012). The ‘On’ state tropomyosin-actin contacts are less well 
characterised and tropomyosin may simply be pushed into its position by strong myosin-actin 
binding. Only few disease-causing mutations are adjacent to the proposed ‘On’ state 
tropomyosin-actin binding sites: the TPM2 mutations p.Asp14Val, p.Glu139del, p.Glu218del 
and the TPM3 mutations p.Leu100Met/Val. Two highly conserved interface residues (Asp137 
in a d position and Glu218 in an a position of the heptad repeat) that cause bends in the 
molecule (Brown et al. 2005) are in α-zones 4 and 6, respectively (Barua et al. 2013). The 
Asp137 is in close proximity of the recurrent mutation p.Glu139del in TPM2. The second one 
Glu218 is the site for deletion (p.Glu218del) in a patient with no clinical details available. In 
addition to actin contacts, these mutations affect the bending of the molecule which has been 
proven to be important for the function. They are likely involved in tropomyosin's interactions 
with F-actin (Brown et al. 2005).   The other prime protein to interact with tropomyosin is 
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troponin T (TnT). TPM2 mutation p.Tyr261Cys and in TPM3 p.Met9Arg are involved in the 
interaction with TnT according to Murakami’s structure of TPM2 (Murakami et al. 2008). 
Tropomyosin head-to-tail polymerization is required for actin binding, and has a role in actin 
filament assembly, and for the regulation of actin-myosin contraction (Murakami et al. 2008). 
TPM2 mutations p.Ala3Gly, p.Lys7del and TPM3 mutations p.Ala4Val, p.Met9Arg and 
p.Stop285Ser/Asn are found at the overlapping region involved in head-to-tail 
polymerization. A similar function has been proposed for the p.K7del mutant in previous 
studies. The N-terminal lysine residues partisipate in the head-to-tail bond between adjacent 
tropomyosin molecules and thus the p.K7del mutation is predicted to affect the ability of β-
tropomyosin to polymerize into long filaments (Mokbel et al. 2013). The p.K7del mutation 
has been predicted to disrupt the N-terminus of the α-helices of dimeric β-tropomyosin, 
altering protein-protein interactions between β-tropomyosin and other molecules and to 
disturb head-to-tail polymerization of β-tropomyosin dimers (Davidson et al. 2013). 
        The charge changes in most hypercontractile mutations are hypothesized to destabilise 
the Off state and favour the equilibrium towards the On state, thus accounting for the higher 
Ca
2+
-sensitivity as was demonstrated for the ACTA1 p.Lys326Asn mutation (Orzechowski, 
Fischer & Lehman 2013). This is shown by the TPM2 mutations p.Lys7del, p.Lys49del, 
p.Arg91Gly, p.Glu139del and p.Glu181Lys, and the TPM3 mutation p.Lys169Glu. This 
correlates with hypercontractile or DA phenotypes which are p.Lys7del, p.Arg91Gly, 
p.Arg133Trp and p.Glu181Lys. Congenital muscle weakness correlates with loss of function 
at the molecular level. These mutations are not at the interface of the Off state but have an 
opposite charge change to the gain-of-function mutations and are in a location that could 
stabilize the Off state relative to the On state. This may account for the loss of function. 
Alteration of the tropomyosin-troponin interface could also have this effect. Mutations shown 
causing decreased Ca
2+
 sensitivity include TPM2-Glu41Lys, TPM2-Glu117Lys, TPM3-
Arg168His and TPM3-Arg245Gly (Figure 12).  
        There is no apparent correlation between conventional disease classification and the 
gain-of-function molecular phenotype, although there were some correlations with the clinical 
picture caused by hyper- and hypocontractile diseases. Among the seven mutations 
investigated, diagnoses include NM, cap myopathy, CFTD, core-rod myopathy and DA. 
When muscle histology provides no clues about the basis of the myopathy, consideration of 
muscle contractility is more predictive, especially for the gain-of-function mutations (Marston 
et al. 2013). This was carefully investigated for the p.Lys7del mutation. Some patients were 
re-diagnosed taking into account the contractility measurements (Mokbel et al. 2013).  Four 
reported mutants in troponins and β-tropomyosin were analysed: Arg63His TnT, Arg91Gly β-
tropomyosin, Arg174Gln TnI, and a TnI truncation mutant (Arg156ter). Thin filaments, 
reconstituted using actin and wt troponin and β-tropomyosin, activated myosin subfragment-1 
ATPase in a calcium-dependent, cooperative manner. Thin filaments containing a troponin or 
β- tropomyosin DA mutant produced significantly enhanced ATPase rates at all calcium 
concentrations without alternating Ca
2+ 
sensitivity or cooperativity. In troponin-exchanged 
skinned fibres, each mutant caused a significant increase in Ca
2+
 sensitivity. It was proposed 
that the mutations cause increased contractility of developing fast-twitch skeletal muscles, 
thus causing muscle contractures and the development of the observed limb deformities 
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(Robinson et al. 2007). These troponin mutations also show the hypercontractile molecular 
phenotype. 
        There are all together 18 mutations at or close to tropomyosin actin binding residues in 
TPM2 (Table 6) and 13 mutations in TPM3 (Table 7) genes. In addition to that both genes 
have one mutation situated at the TnT binding site (Tables 6 and 7). This indicates that 
perturbations in the interactions of the proteins in the sarcomere is an important disease 
mechanism in congenital myopathies. We conclude that most of the disease causing mutations 
show association with actin binding residues in α- and β-tropomyosin.   
 
 
 
Figure 12. On-state actin-tropomyosin contacts and disease mutations. The Tm2 (β-Tm) sequence and 
the Tm3 (γ-Tm) sequence divided into the α- and β-bands as defined by Mclachlan and Stewart 
(1976). The purple circles highlight residues interacting with actin Asp25; the orange circles highlight 
the residues interacting with actin R147, K326 and K328 as defined by Li et al (2010). The Tm2 
mutations are written above the sequence. The mutations increasing Ca
2+
-sensitivity are written in 
green, while those decreasing it are in black. Tm overlapping regions are shown by light blue boxes.  
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4.4 Identification of novel phosphorylation sites in β-tropomyosin 
To study the potential role of tropomyosin phosphorylation on pathogenesis, we performed 
mass spectrometry analyses on purified recombinant tropomyosin, both wt β-tropomyosin and 
proteins containing known patient mutations (p.Glu41Lys, p.Lys49del, p.Glu117Lys, 
p.Glu139del and p.Gln147Pro). In addition to four known phosphorylation sites (p.Thr53, 
p.Thr252, p.Thr282 and p.Ser283) that were present in both the wt and the mutated proteins 
(Dai et al., 2007; Huttlin et al., 2010), we identified four novel phosphorylation sites 
(p.Thr79, p.Thr108, p.Ser158 and p.Ser206). The previously unknown phosphorylation sites 
are situated in the mid-region of β-tropomyosin around the mutational hotspot in or near the 
fourth α-zone. The phosphorylation patterns were identical between the wt and the mutated 
proteins, indicating that changes in phosphorylation patterns are not the main cause of disease 
for the mutations studied. Also, no patient mutations have been found in the phosphorylated 
residues in β-tropomyosin and α-tropomyosin (Table 8). 
 
Table 8. Phosphorylation sites in β-tropomyosin (Tm2). The novel sites were found in both wild type 
Tm2 and five mutants, Glu41Lys, Lys49del, Glu117Lys, Glu139del and Gln147Pro. IS represents the 
ion score in the Mascot search and the threshold value 40 was chosen.  
 
Human  Mouse  Present 
study 
   
Site Reference Site Reference Known 
site 
IS Novel 
site 
IS 
T53-P www.phosphosite.org S87-P Huttlin, E.L. 2010; 
Hsu, P.P. 2011 
T53-P 46 T79-P 69 
S63-P www.phosphosite.org Y162-
P 
www.phosphosite.org T252-P 59 T108-
P 
60 
S87-P Brill, L.M. 2009 T252-
P 
Dai, J. 2007 T282-P 74 S158-
P 
58 
Y162-P Rikova, K. 2007 Y261-
P 
www.phosphosite.org S283-P 48 S206-
P 
56 
Y261-P Iliuk, A.B. 2010 T282-
P 
Dai, J. 2007; Huttlin, 
E.L. 2010 
    
  S283-
P 
Dai, J. 2007; 
Zanivan, S. 2008; 
Huttlin, E.L. 2010 
    
 
 
Phosphorylation has been shown to have an impact on tropomyosin function: it enhances 
head-to-tail interaction of neighbouring tropomyosin dimers and increases binding to troponin 
T (Heeley et al. 1989, Hayley et al. 2008). There are conflicting results for the effect of 
phosphorylation on the activation of thin filaments by Ca
2+
. In studies on muscle fibres with 
thin filament replacement, cooperativity was not significantly affected, but in fluorescence 
studies phosphorylation was shown to slow relaxation of Ca
2+
 activated force (Heeley 2013). 
Transgenic animal models have revealed a possible connection between heart disease and 
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phosphorylation. Mice expressing tropomyosin mutants p.Glu54Lys and p.Asn175Asp 
showed altered levels of phosphorylation compared with controls (Muthuchamy et al. 1999, 
Warren et al. 2008). 
 
4.5 Functional analysis by in vitro motility assay  
In vitro motility assay (IVMA) analyses the movement of fluorescently labelled thin filaments 
over a bed of immobilized heavy meromyosin (Fraser, Marston 1995). Thin filaments were 
constracted using rabbit skeletal actin and troponin, together with the baculovirus-expressed 
wt or mutant β-tropomyosin homodimers. It was observed with wt thin filaments that both the 
speed of filament sliding over myosin and the fraction of filaments that are motile are 
regulated by Ca
2+
. The troponin–tropomyosin complex inhibits the movement of thin 
filaments under relaxing conditions (Ca
2+
 ~ 10
−9
 M) so that the fraction motile is 10% or less. 
At activating Ca
2+
 concentrations (3.5 μM) at least 80% of filaments are motile, like actin 
alone. The sliding speed also increases 2-fold between relaxing and activating Ca
2+
 
concentrations. 
        When mutant β-tropomyosin p.Lys49del, p.Glu139del and p.Gln147Pro were 
incorporated into thin filaments, it was found that motility was not switched off in low Ca
2+
 
even with high tropomyosin concentrations. Thin filaments with the wt β-tropomyosin 
switched off at the standard tropomyosin concentration indicating that the abnormal function 
was due to the mutation in tropomyosin. The β-tropomyosin mutants p.Lys49del, p.Glu139del 
and p.Gln147Pro appeared to have a lower affinity for actin compared with the wt. This was 
also indicated by the direct measurements in actin binding experiments. Thin filaments 
containing the β-tropomyosin mutations p.Glu41Lys and p.Glu117Lys that bound strongly to 
actin were able to regulate the filaments, with low Ca
2+
 concentration causing a complete 
switch off of their motility.  
       Another study of the proposed gain-of-function mutations, i.e. a mutation that changes 
the gene product such that it gains a new and abnormal function (p.Lys49del, p.Arg91Gly, 
p.Glu139del and p.Lys169Glu), produced a higher Ca
2+
 sensitivity and a higher maximum 
sliding speed (Marston et al. 2013).  This was also the case with the previously investigated 
gain-of-function mutations p.Lys7del (Mokbel et al. 2013) and p.Glu181Lys (Ochala et al. 
2012b). In contrast, skeletal muscle myopathy mutations (p.Glu41Lys and p.Glu117Lys in β-
tropomyosin and p.Arg168His and p.Arg245Gly in γ-tropomyosin encoded by TPM1) that 
were expected to give a hypocontractile phenotype showed lower Ca2+ sensitivity and lower 
sliding speed (Marston et al. 2013).  
        Pharmacological modulators of TnC, also called Ca
2+
 sensitizers, have been tested in 
vitro and in vivo for heart disease. They have been proven to minimize the effect of cardiac 
contractile dysfunction by restoring the impaired cell Ca
2+
 sensitivity. The molecular 
mechanisms behind Ca
2+
 sensitizers are variable, for example binding to troponin C 
prolonging the time perioid of the open state. This stabilizes the Ca
2+
 induced conformation of 
the troponin complex, increasing force generation capacity in cardiac muscle (Ochala 2010). 
These agents may potentially be useful also for other patients with mutations causing 
decreased Ca
2+ 
sensitivity.   
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4.6 Mass spectrometry and three-dimensional models 
Two of the purified β-tropomyosin samples run on SDS/PAGE gels (p.Lys49del and 
p.Glu139del) showed slower migration than the wt and other mutant proteins. To find out 
wether the difference in migration could be due to post-transcriptional modifications, in-gel 
digestion of the proteins was used followed by LC-MS/MS analysis of the resulting peptides. 
The mass-spectrometric database (http://www.phosphosite.org) contained eight 
phosphorylation sites that had been found in mouse and human tropomyosin. Four novel 
phosphorylation sites were found in addition to previously identified ones. They were present 
in all samples including the wt. No other significant differences in peptide mass were found. 
The protein modifications caused by the mutations and the N-terminal acetylation of the 
tropomyosins known to be important in head-to-tail binding (Perry 2001) were verified using 
LC-MS/MS. Post-transcriptional modifications were not found to be the reason for the 
difference in migration. Instead, the reason appeared to be a change in the secondary structure 
conformation of the p.Lys49del and p.Glu139del mutants, as was previously found with the 
p.Asp175Asn mutation in α-tropomyosin (Bottinelli et al. 1998). Confirmation that the 
aberrant migration of the recombinant p.Asp175Asn α-tropomyosin protein reflects the 
impact of only the single residue substitution was proven in identical observations on SDS-
PAGE electrophoresis of recombinant wt and p.Asp175Asn mutant chicken α- tropomyosin 
(Bottinelli et al. 1998). Therefore, in this study three-dimensional models of the differentially 
migrating mutants were created. The molecular models created showed that α-helical 
conformation was changed in the p.Lys49del and p.Glu139del mutants compared with wt 
structure. The p.Glu41Lys mutant was used as comparison to show that not all mutants result 
in gross effect on the secondary structure (Figure 13). 
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Figure 13. Structural alignments of wt and mutant tropomyosin using the Discovery Studio 2.1 
program. The mutations K49del (A), E139del (B and C) and E41K (D) were made in rat Tm2 
(P58775.1) and were superimposed over the wt structure 1C1GA (A, C and D) or 2B9CA (B). 2B9CA 
was used as it provided a better resolution. Amino acids before deletions are marked in deletion 
mutants and E41 in E41K. Amino acids used in comparison are shown. Modified from Biochem J. 
2012 15;442(1):231-9 with permission from the Biochemical Society. 
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4.7 Circular dichroism spectra of β-tropomyosin 
 To further study the structures of the mutant proteins, and the effect of disease causing 
mutations on overall secondary structure, circular dichroism (CD) spectra were produced. At 
+20°C all recombinant tropomyosin proteins showed CD spectra characteristic of α-helical 
proteins, featuring a minimum at 222 and 208 nm and a maximum at 190 nm. At +20°C wt 
tropomyosin had a calculated α-helical content of 97.3±2.8%. E117K, which shows increased 
actin binding, displayed an α-helical content higher than that of the wt (99.8±0.2%). Two of 
the mutant proteins displayed lower calculated α-helical content: E139del (79.5±0.7%) and 
K49del (84.6±3.1%), which also showed aberrant migration on SDS-PAGE. 
        At +37°C wt and mutant tropomyosin proteins also displayed CD spectra characteristic 
of α-helical proteins. wt tropomyosin was calculated to be 81.9±1.8% α-helical, whereas the 
Q147P and p.Glu117Lys showed the highest α-helical contents (88.3±0.8% and 87.9±4.3% 
respectively). The lowest α-helical contents were seen with the K49del and E139del mutants 
(65.0±1.6% and 68.2±1.2% respectively). At both of the temperatures used, K49del and 
E139del displayed lower α-helical content than wt tropomyosin. p.Glu117Lys showed higher 
α-helical content than wt at both temperatures and Q147P at +37°C (Figure 14). 
        The circular dichroism was used to investigate the secondary structure of p.Lys7del 
mutant. The results indicate that p.Lys7del and wt β-tropomyosin are folded in solution and 
are predominantly α-helical. The secondary structure of p.Lys7del mutant was not changed by 
the mutation (Mokbel et al. 2013). This shows that not all the mutations, even as deleterious 
as a deletion, have an impact on the secondary structure of β-tropomyosin. 
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Figure 14. Circular dicroism (CD) spectra (250–190 nm) of tropomyosins measured at 20°C and 
37°C. Modified from Biochem J. 2012 15;442(1):231-9. Modified from Marttila et al. 2012 Biochem 
J. 15;442(1):231-9 with permission from the Biochemical Society. 
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4.8 Nebulin interactions with actin and tropomyosin  
We wanted to study the function of nebulin mutations causing NM and distal myopathy. In 
this study nebulin mutations causing NM and distal myopathy were investigated on their 
ability to bind actin and tropomyosin. Due to the enormous size of nebulin, functional studies 
of full-length nebulin are difficult and we opted for studying protein domains (super repeats) 
with introduced mutations.  
 
4.8.1 Nebulin-actin affinity 
Super repeat 9 of nebulin containing the p.Glu2431Lys (exon 54, c.7291G>A) mutation, and 
nebulin super repeat 9 lacking 35 amino acids due to deletion of the entire exon 55 
(p.Arg2478_Asp2512del, c.7431+1916_7536+372del), showed consistently reduced affinity 
for F-actin compared with the wt fragments, but the reduction was not statistically significant 
using the Kruskal-Wallis test. The p.Ser6366Ile (exon 122, c.19097G>T) mutation in super 
repeat 18 at an actin-binding site showed increased actin affinity (P=0.048). Super repeat 14 
containing an in-frame deletion of six amino acids (exon 78, p.Val3924_Asn3929del) and 22 
containing the p.Thr7382Pro (exon 151, c.22144A>C) mutation did not show any change in 
affinity for actin compared to the wt fragments (Figure 15). 
 
 
 
 
Figure 15. Mutations affect nebulin binding to F-actin. Nebulin protein domains were incubated with 
F-actin and centrifuged. Pellet and supernatant fractions were separated, run on SDS-PAGE gels and 
stained with Coomassie Blue. The relative intensity of nebulin protein in the pellet was quantified 
from three independent experiments. The mean value and standard deviations from three experiments 
are shown in the bar chart to the left, and gel pictures of representative experiments are shown to the 
right. Nebulin domains containing the mutation p.Ser6366Ile (ex122m) showed significantly increased 
actin affinity (P value 0.048). P values were calculated using the Kruskal-Wallis test when comparing 
three groups (S9) and the Mann-Whitney test when comparing two groups (S14, S18, S22). Asterisks 
mark significant differences compared with the wt protein. Modified from Marttila et al. 2014 Skeletal 
Muscle 1;4:15. 
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The mutation p.Glu117Lys was found to have stronger affinity for actin than wt β-
tropomyosin. Tighter binding was speculated to result in the sarcomeric proteins remaining in 
the thin filaments and the Z disc, and not forming nemaline bodies (Marttila et al. 2012). The 
contractile deficiency at the level of the troponin switch parallels that previously reported for 
CFTD mutations (Clarke et al. 2007). Immunofluorescence confocal microscopy studies on 
mice with nebulin exon 55 deleted revealed that thin filament length is significantly reduced 
(Ottenheijm et al. 2013). This is one of the pathogenetic mechanisms causing severe muscle 
weakness in exon 55 deleted mice. In our study the affinity for F-actin was consistently reduced, but 
was not shown to be statistically significant. Nebulin fragments used in the binding experiments are 
easily degradable resulting in great deviation between the results but they all showed reduced affinity 
to F-actin. With more replication of the experiments, the statistical power would have been increased 
and we could perhaps have been able to prove that reduced actin affinity would be the other 
pathogenetic factor in the disease process. 
 
4.8.2 Nebulin-tropomyosin affinity 
We tested nebulin affinity to tropomyosin using four wt nebulin super repeats (9, 14, 18 and 
22) and wt α- and β-tropomyosins. All four nebulin super repeats bound to tropomyosin with 
high affinity. This is the first direct evidence that there is a tropomyosin binding motif in 
these super repeats of nebulin (Marttila et al. 2014b). 
        Super repeat 9 containing the p.Glu2431Lys mutation consistently showed higher 
affinity for tropomyosin but this was not shown to be statistically significant.  The in-frame 
deletion of exon 55 (p.Arg2478_Asp2512del) in super repeat 9 and the in-frame deletion 
p.Val3924_Asn3929del in super repeat 14 showed slight, but not statistically significant,  
increase in affinity for tropomyosin. Super repeat 18 containing the p.Ser6366Ile mutation 
displayed similar affinity for tropomyosin as wt fragments. The nebulin exon 151 containing 
super repeat 22 with the missense mutation p.Thr7382Pro showed greatly reduced affinity for 
tropomyosin compared with the wt protein fragment (P=0.039) (Figure 16). Proline is not 
present in any wt β-tropomyosin or in coiled-coil proteins in general, as it produces a kink in 
the coiled-coil helix (East et al. 2010). The β-tropomyosin mutant p.Gln147Pro bound actin 
significantly weaker than the wt β-tropomyosin, which is to be expected with the disruption of 
the continuous α-helix (Marttila et al. 2012). Since the nebulin repeat regions have been 
shown to have transient α-helical conformations (Pfuhl, Winder & Pastore 1994), the 
p.Thr7382Pro mutation could similarly disrupt the structure in nebulin.  
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Figure 16. Nebulin mutations affect binding to tropomyosin. Purified GST-nebulin domains bound to 
beads were incubated with purified α- and β-tropomyosin, beads were washed and bound proteins run 
on SDS-PAGE gels and stained with Coomassie Blue. The relative intensity of bound α- and β-
tropomyosin was quantified from three independent experiments. The mean value and standard 
deviations from three experiments are shown in the bar chart on the left and gel pictures of 
representative experiments are shown on the right. Nebulin domains containing the p.Thr7382Pro 
(ex151m) mutation showed significantly lower affinity to tropomyosin than wt proteins (P value 
0.039).  P values were calculated using the Kruskal-Wallis test when comparing three groups (S9) and 
the Mann-Whitney test when comparing two groups (S14, S18, S22). Asterisks mark significant 
differences compared with the wt protein. Modified from Marttila et al. 2014 Skeletal Muscle 1;4:15. 
 
When testing the affinity of wt nebulin super repeats for wt and six β–tropomyosin mutants 
(p.Lys7del, p.Glu41Lys, p.Lys49del, p.Glu117Lys, p.Glu139del and p.Gln147Pro) nebulin 
super repeat 18 containing the wt exon 122 consistently showed slightly reduced affinity for 
the β-tropomyosin Glu41Lys mutant, but using the Kruskal-Wallis test this was not shown to 
be statistically significant. The other mutant tropomyosins did not show significant changes in 
binding affinity for wt nebulin compared with wt tropomyosin (Figure 17).  
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Figure 17. Nebulin wt super repeat domain affinity for mutant tropomyosins. Purified GST-nebulin 
domains bound to beads were incubated with purified α- and β-tropomyosin, beads were washed and 
bound proteins run on SDS-PAGE gels and stained with Coomassie Blue. The relative intensity of 
bound α- and β-tropomyosin was quantified from three independent experiments. The mean values 
and standard deviations from three experiments are shown in the bar chart to the left, and gel pictures 
of representative experiments are shown on the right. No statistically significant differences in binding 
affinities were found. Modified from Marttila et al. 2014 Skeletal Muscle 1;4:15. 
 
        The mechanical studies using skinned muscle fibres revealed that NEB knockout mice 
fibres had increased tension cost and reductions in calcium sensitivity and cooperativity of 
activation. The findings indicate that in skeletal muscle, nebulin increases thin filament 
activation, and through altering cross-bridge cycling kinetics, nebulin increases the force and 
efficiency of contraction (Chandra et al. 2009). In nebulin exon55del mice it has been shown 
that regulation of contraction is impaired by marked changes in crossbridge cycling kinetics 
and by a reduction of the calcium sensitivity of force generation (Ottenheijm et al. 2013). It 
would be interesting to test whether any of the other nebulin mutations 
(p.Val3924_Asn3929del, c.7291G>A, c.19097G>T, c.22144A>C) would have such effects. 
Cardiac α-actin over-expression therapy worked for some mutations in ACTA1 causing NM 
(Ravenscroft et al. 2013a). This would not be easily applied to nebulin caused NM due to the 
large size of the gene.  
        The X-ray diffraction patterns of human membrane-permeabilized single muscle fibres 
expressing nebulin mutations g.6357dupT and g.47420A>C were recorded and analyzed. 
Results demonstrated that, during contraction, the cycling rate of myosin heads attaching to 
actin was dramatically perturbed, causing a reduction in the fraction of myosin-actin 
interactions in the strong binding state. This reduces the force-generating capacity and 
provokes muscle weakness (Ochala et al. 2011). Fast skeletal muscle troponin activator CK-
2066260, has been investigated as a potential therapeutic agent of nebulin-caused NM. 
Nebulin protein concentrations were severely reduced in muscle cells from patients treated 
with the troponin activator compared with controls, while myofibrillar ultrastructure was 
largely preserved. Both maximal active tension and the calcium-sensitivity of force generation 
were lower in patients compared to controls. CK-2066260 greatly increased the Ca
2+
 
sensitivity of force generation without affecting the cooperativity of activation in patients, to 
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levels that exceed those observed in untreated control muscle. This implies that CK-2066260 
could be used as a therapeutic agent for NM caused by nebulin, but further studies are needed 
(de Winter et al. 2013). 
        Recent advances in research show that abnormal excitation-contraction coupling may be 
a common phenomenon in the congenital myopathies, either as a result of malformed 
contractile filaments in the NMs or disruption of Ca
2+
 homeostasis at the level of the triad in 
the centronuclear/myotubular and core myopathies (Nance et al. 2012). Our results suggest 
that the disease-causing mutations have a great impact on the structure and function of the 
thin filaments. 
 
4.9 Conclusions and future prospects 
We show that most TPM mutations affect actin association (18/30 in TPM2, 13/20 in TPM3),  
causing NM, cap myopathy, core-rod myopathy, CFTD, CM, DA and Escobar syndrome with 
myopathy. Six mutations resulted in increased Ca
2+
 sensitivity and hypercontractile 
phenotypes. Amongst the remaining mutations, all 5 so far tested caused decreased Ca
2+
 
sensitivity. Three of the TPM2 and four of the TPM3 mutations were located in the 
tropomyosin overlapping region affecting head-to-tail binding.  
        We report 4 novel phosphorylation sites in β-tropomyosin. Although phosphorylation is 
known to be linked to tropomyosin-actin association, we found no mutations in 
phosphorylated residues, nor altered phosphorylation patterns in purified tropomyosin 
proteins containing known patient mutations.  
       There was no clear relationship between conventional disease classification and the gain-
of-function phenotype but there were clinical correlations with hypercontractile versus non-
hypercontractile molecular phenotypes. In many cases the muscle histology does not provide 
clear cut diagnosis because of the overlap in muscle histology. 
        Patients with TPM2 mutations tended to present with milder symptoms than those with 
TPM3 mutations and DA was present only in the TPM2 group. Recessive disease was usually 
more severe than the dominantly inherited forms.  FSD was consistent in the TPM3 group and 
common also with mutations of TPM2. Patients with hypercontractile molecular phenotypes 
more often had contractures of the limb joints and jaw than those with non-hypercontractile 
molecular phenotypes, while those with no hypercontractility more commonly had spinal 
deformities or rigidity. There was no difference in age of onset. 
        In the study of tropomyosin-actin affinity, actin binding was weak in three of five 
mutants suggesting that abnormal binding between actin and aberrant tropomyosin is the 
pathogenetic mechanism causing muscle weakness in these patients. Ca
2+
 activation of 
contractility was defective in the two other mutants, suggesting an alternative cause of 
contractile dysfunction. In future studies, human tissue cultures could be used for studying the 
early stages of altered myofibrillogenesis and morphological changes linked to myopathy-
related tropomyosin mutants.  
        The X-ray diffraction patterns of human membrane permeabilized muscle cells 
expressing β-tropomyosin mutation p.Glu41Lys were measured. The results indicated that, in 
the presence of the p.Glu41Lys β-tropomyosin mutation, the myofilament lattice geometry is 
well maintained and therefore may not have any detrimental influence on the contraction 
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mechanisms. The X-ray diffraction pattern investigations could be broadened to other β-
tropomyosin mutations used in our studies (p.Lys49del, p.Glu117Lys, p.Glu139del and 
p.Gln147Pro), which exhibited changes in their 3D structure (p.Lys49del and p.Glu139del) 
and Ca
2+ 
sensitivity (p.Glu117Lys).  
        The last study demonstrates the results of nebulin-actin and nebulin-tropomyosin 
interactions in vitro, and shows that mutations in nebulin and tropomyosin can alter these 
interactions. Both actin and tropomyosin binding affinity was affected by nebulin mutations. 
This suggests that abnormal interaction between aberrant thin filament proteins is a 
pathogenetic mechanism in NM and related disorders. However, we only studied nebulin 
superrepeats 9, 14, 18 and 22 and five disease mutations in these domains. There are currently 
211 mutations known in nebulin. In the future it would be interesting to study the interactions 
of more disease mutations with actin and tropomyosin to see how common aberrant binding 
of thin filament proteins is as a disease mechanism. The protein interaction studies could 
include additional proteins such as the pointed-end capping protein tropomodulin and the 
troponins. The phosphorylation studies could be broadened to include nebulin, since 
phosphorylation has been shown to be critical for normal cardiac telethonin function. We 
could also use X-ray diffraction studies to investigate the effect of further mutations on 
contractility. Improving our understanding of the mechanisms underlying muscle weakness in 
patients with NM, mouse or zebrafish models that harbour mutations in nebulin found in 
patients should be further developed. 
        Our studies have added to the knowledge of the pathogenetic mechanisms underlying 
congenital myopathies caused by mutations in the tropomyosin and nebulin genes. In addition 
we have collected the known and novel mutations in the TPM2 and TPM3 genes and 
presented genotype-phenotype correlations. 
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lukuisia reissuja uimaan, leikkipuistoihin ja futistreeneihin sillä aikaa kun olen kirjoittanut. 
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